<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Coenzyme Q10 for heart failure - Al Saadi, T - 2021 | Cochrane Library</title> <meta content="Coenzyme Q10 for heart failure - Al Saadi, T - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008684.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Coenzyme Q10 for heart failure - Al Saadi, T - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008684.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008684.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Coenzyme Q10 for heart failure" name="citation_title"/> <meta content="Tareq Al Saadi" name="citation_author"/> <meta content="University of Illinois at Chicago/Advocate Christ Medical Center" name="citation_author_institution"/> <meta content="Yazan Assaf" name="citation_author"/> <meta content="yazan.assaf.mail@gmail.com" name="citation_author_email"/> <meta content="Medhat Farwati" name="citation_author"/> <meta content="Khaled Turkmani" name="citation_author"/> <meta content="Ahmad Al-Mouakeh" name="citation_author"/> <meta content="University of Aleppo" name="citation_author_institution"/> <meta content="Baraa Shebli" name="citation_author"/> <meta content="University of Aleppo" name="citation_author_institution"/> <meta content="Mohammed Khoja" name="citation_author"/> <meta content="Adib Essali" name="citation_author"/> <meta content="Counties Manukau Health" name="citation_author_institution"/> <meta content="Mohammed E Madmani" name="citation_author"/> <meta content="University of Arkansas for Medical Sciences" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD008684.pub3" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/02/03" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008684.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008684.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008684.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Ataxia; *Heart Failure [drug therapy]; Mitochondrial Diseases; Muscle Weakness; *Myocardial Infarction [drug therapy]; Quality of Life; *Stroke; Stroke Volume; Ubiquinone [adverse effects, analogs &amp; derivatives, deficiency]; Ventricular Function, Left" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008684.pub3&amp;doi=10.1002/14651858.CD008684.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="9nGOjNGw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008684\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008684\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008684\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008684\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ko","ms","hr","fr","zh_HANS","zh_HANT","th","ja","fa","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008684.pub3",title:"Coenzyme Q10 for heart failure",firstPublishedDate:"Feb 3, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008684.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008684.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008684.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008684.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008684.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008684.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008684.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008684.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008684.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008684.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11947 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008684.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/full#CD008684-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/full#CD008684-sec-0086"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/full#CD008684-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/full#CD008684-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/full#CD008684-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/full#CD008684-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/full#CD008684-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/full#CD008684-sec-0078"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/appendices#CD008684-sec-0091"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/supinfo/CD008684StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/supinfo/CD008684StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Coenzyme Q10 for heart failure</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/information#CD008684-cr-0004">Tareq Al Saadi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/information#CD008684-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Yazan Assaf</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/information#CD008684-cr-0006">Medhat Farwati</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/information#CD008684-cr-0007">Khaled Turkmani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/information#CD008684-cr-0008">Ahmad Al-Mouakeh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/information#CD008684-cr-0009">Baraa Shebli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/information#CD008684-cr-0010">Mohammed Khoja</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/information#CD008684-cr-0011">Adib Essali</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008684.pub3/information#CD008684-cr-0012">Mohammed E Madmani</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/information/en#CD008684-sec-0096">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 03 February 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008684.pub3">https://doi.org/10.1002/14651858.CD008684.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008684-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008684-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008684-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008684-abs-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008684-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008684-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD008684-abs-0016">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008684-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008684-abs-0001" lang="en"> <section id="CD008684-sec-0001"> <h3 class="title" id="CD008684-sec-0001">Background</h3> <p>Coenzyme Q10, or ubiquinone, is a non‐prescription nutritional supplement. It is a fat‐soluble molecule that acts as an electron carrier in mitochondria, and as a coenzyme for mitochondrial enzymes. Coenzyme Q10 deficiency may be associated with a multitude of diseases, including heart failure. The severity of heart failure correlates with the severity of coenzyme Q10 deficiency. Emerging data suggest that the harmful effects of reactive oxygen species are increased in people with heart failure, and coenzyme Q10 may help to reduce these toxic effects because of its antioxidant activity. Coenzyme Q10 may also have a role in stabilising myocardial calcium‐dependent ion channels, and in preventing the consumption of metabolites essential for adenosine‐5'‐triphosphate (ATP) synthesis. Coenzyme Q10, although not a primary recommended treatment, could be beneficial to people with heart failure. Several randomised controlled trials have compared coenzyme Q10 to other therapeutic modalities, but no systematic review of existing randomised trials was conducted prior to the original version of this Cochrane Review, in 2014. </p> </section> <section id="CD008684-sec-0002"> <h3 class="title" id="CD008684-sec-0002">Objectives</h3> <p>To review the safety and efficacy of coenzyme Q10 in heart failure.</p> </section> <section id="CD008684-sec-0003"> <h3 class="title" id="CD008684-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, Web of Science, CINAHL Plus, and AMED on 16 October 2020; ClinicalTrials.gov on 16 July 2020, and the ISRCTN Registry on 11 November 2019. We applied no language restrictions. </p> </section> <section id="CD008684-sec-0004"> <h3 class="title" id="CD008684-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials of either parallel or cross‐over design that assessed the beneficial and harmful effects of coenzyme Q10 in people with heart failure. When we identified cross‐over studies, we considered data only from the first phase. </p> </section> <section id="CD008684-sec-0005"> <h3 class="title" id="CD008684-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods, assessed study risk of bias using the Cochrane 'Risk of bias' tool, and GRADE methods to assess the quality of the evidence. For dichotomous data, we calculated the risk ratio (RR); for continuous data, the mean difference (MD), both with 95% confidence intervals (CI). Where appropriate data were available, we conducted meta‐analysis. When meta‐analysis was not possible, we wrote a narrative synthesis. We provided a PRISMA flow chart to show the flow of study selection. </p> </section> <section id="CD008684-sec-0006"> <h3 class="title" id="CD008684-sec-0006">Main results</h3> <p>We included eleven studies, with 1573 participants, comparing coenzyme Q10 to placebo or conventional therapy (control). In the majority of the studies, sample size was relatively small. There were important differences among studies in daily coenzyme Q10 dose, follow‐up period, and the measures of treatment effect. All studies had unclear, or high risk of bias, or both, in one or more bias domains. We were only able to conduct meta‐analysis for some of the outcomes. None of the included trials considered quality of life, measured on a validated scale, exercise variables (exercise haemodynamics), or cost‐effectiveness. </p> <p>Coenzyme Q10 probably reduces the risk of all‐cause mortality more than control (RR 0.58, 95% CI 0.35 to 0.95; 1 study, 420 participants; number needed to treat for an additional beneficial outcome (NNTB) 13.3; moderate‐quality evidence). </p> <p>There was low‐quality evidence of inconclusive results between the coenzyme Q10 and control groups for the risk of myocardial infarction (RR 1.62, 95% CI 0.27 to 9.59; 1 study, 420 participants), and stroke (RR 0.18, 95% CI 0.02 to 1.48; 1 study, 420 participants). </p> <p>Coenzyme Q10 probably reduces hospitalisation related to heart failure (RR 0.62, 95% CI 0.49 to 0.78; 2 studies, 1061 participants; NNTB 9.7; moderate‐quality evidence). </p> <p>Very low‐quality evidence suggests that coenzyme Q10 may improve the left ventricular ejection fraction (MD 1.77, 95% CI 0.09 to 3.44; 7 studies, 650 participants), but the results are inconclusive for exercise capacity (MD 48.23, 95% CI ‐24.75 to 121.20; 3 studies, 91 participants); and the risk of developing adverse events (RR 0.70, 95% CI 0.45 to 1.10; 2 studies, 568 participants). </p> <p>We downgraded the quality of the evidence mainly due to high risk of bias and imprecision.</p> </section> <section id="CD008684-sec-0007"> <h3 class="title" id="CD008684-sec-0007">Authors' conclusions</h3> <p>The included studies provide moderate‐quality evidence that coenzyme Q10 probably reduces all‐cause mortality and hospitalisation for heart failure. There is low‐quality evidence of inconclusive results as to whether coenzyme Q10 has an effect on the risk of myocardial infarction, or stroke. Because of very low‐quality evidence, it is very uncertain whether coenzyme Q10 has an effect on either left ventricular ejection fraction or exercise capacity. There is low‐quality evidence that coenzyme Q10 may increase the risk of adverse effects, or have little to no difference. </p> <p>There is currently no convincing evidence to support or refute the use of coenzyme Q10 for heart failure. Future trials are needed to confirm our findings. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008684-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008684-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD008684-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD008684-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008684-abs-0020">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008684-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008684-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008684-abs-0018">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008684-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008684-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD008684-abs-0021">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008684-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD008684-abs-0017">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008684-abs-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008684-abs-0015">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008684-abs-0002" lang="en"> <h3>Coenzyme Q10 for heart failure</h3> <p>Heart failure is a term used to describe the state that develops when the heart cannot maintain adequate cardiac output, or can do so only at the expense of overfilling the heart chambers. People with heart failure commonly experience a relapsing and remitting disease course, with periods of stability and episodes of decompensation (failure to cope with heart damage), leading to worsening symptoms that necessitate hospitalisation. </p> <p>Treatment options for heart failure range from drugs to heart transplantation, with each having its own limitations. Coenzyme Q10 (or ubiquinone) has been suggested as a treatment option in some trials. Coenzyme Q10 is a non‐prescription nutritional supplement. It is a fat‐soluble molecule that has a role in energy production within the cells of the body. It may also have antioxidant properties. </p> <p>Low levels of coenzyme Q10 may be related to the severity of heart failure. Coenzyme Q10 has been found in all tissues and organs in the body, with the highest concentrations in the heart. Emerging data have suggested that the harmful effects of reactive oxygen species (unstable molecules that contains oxygen and easily reacts with other molecules) are increased in people with heart failure. Because of its antioxidant activity, coenzyme Q10 may help to reduce these toxic effects, which damage the components of the cardiac cells, and disrupt cellular signalling. Coenzyme Q10 plays an important role in conducting signals within the heart muscle and in generating energy.The concentration of coenzyme Q10 has been inversely related to the severity of heart failure. Supplementation with coenzyme Q10 may improve heart failure. Coenzyme Q10 is sometimes used because it is thought to have an acceptable safety profile, with no significant side effects. </p> <p>We conducted this review to assess the available evidence on the effects of coenzyme Q10 in people with heart failure. We included 11 randomised controlled trials, involving 1573 participants. They were relatively small, and followed up participants for a relatively short period of time. The analyses show that coenzyme Q10 probably reduces the risk of mortality from all causes, and hospitalisations due to heart failure. It may result in increased, or little or no difference in the risk of myocardial infarction, stroke, or adverse events. The effect of coenzyme Q10 on cardiac function and symptom improvement is uncertain. </p> <p>The evidence, current to October 2020, is of a moderate quality at best, because of the high risk of bias in some of the included studies and the absence of precise and consistent results. There is currently no convincing evidence to support or refute the use of coenzyme Q10 for heart failure. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008684-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008684-sec-0086"></div> <h3 class="title" id="CD008684-sec-0087">Implications for practice</h3> <section id="CD008684-sec-0087"> <p>The currently available evidence is not sufficient to draw robust conclusions about the safety and efficacy of coenzyme Q10 in heart failure. </p> <p>Included studies provide moderate‐quality evidence for a probable benefit for coenzyme Q10 in reducing all‐cause mortality, cardiovascular mortality, and hospitalisation for heart failure. The results were inconclusive for risk of myocardial infarction, stroke, or revascularisation procedures. </p> <p>With very low‐quality evidence, it is very uncertain whether coenzyme Q10 has an effect on left ventricular ejection fraction or exercise capacity. Coenzyme Q10 may raise serum levels of coenzyme Q10, however, there is significant heterogeneity. Coenzyme Q10 appeared to lower BNP but not NT‐proBNP blood levels. For adverse events, there is a low‐quality evidence that coenzyme Q10 may result in possible harm, or little to no difference. </p> </section> <h3 class="title" id="CD008684-sec-0088">Implications for research</h3> <section id="CD008684-sec-0088"> <p>There is a need for high quality, randomised controlled trials with large sample size, comparing coenzyme Q10 to placebo. Such studies should focus on long‐term high‐yield outcomes, especially mortality, cardiovascular events, hospitalisations, and side effects. It would also be helpful to examine similar doses of coenzyme Q10, and unified measures of treatment effects across the studies to allow for meta‐analyses. Comprehensive reporting of the results of such studies is also key. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008684-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008684-sec-0008"></div> <div class="table" id="CD008684-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Coenzyme Q10 compared to placebo or conventional therapy for heart failure</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Coenzyme Q10 compared to placebo or conventional therapy for heart failure</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with heart failure<br/><b>Setting:</b> outpatient departments<br/><b>Intervention:</b> coenzyme Q10<br/><b>Comparison:</b> placebo or conventional therapy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or conventional therapy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with coenzyme Q10</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/><i>follow‐up: 26 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.58<br/>(0.35 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>420<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Coenzyme Q10 probably reduces all‐cause mortality</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>179 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000<br/>(63 to 170) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Myocardial infarction</b><br/><i>follow‐up: 26 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.62<br/>(0.27 to 9.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>420<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The results for the effect of coenzyme Q10 on risk of myocardial infarction are inconclusive.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000<br/>(2 to 88) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/><i>follow‐up: 26 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.18<br/>(0.02 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>420<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The results for the effect of coenzyme Q10 on risk of stroke are inconclusive.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/>(1 to 41) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hospitalisation for heart failure</b><br/><i>follow‐up: mean 19 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.62<br/>(0.49 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1061<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Coenzyme Q10 probably reduces hospitalisation for heart failure.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>276 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>171 per 1000<br/>(135 to 215) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Left ventricular ejection fraction (%)</b><br/><i>follow‐up: mean 8 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.77 higher<br/>(0.09 higher to 3.44 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>650<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d</sup><sup>,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of coenzyme Q10 on left ventricular ejection fraction (%). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exercise capacity</b> <br/><b>(assessed with treadmill exercise test (duration in seconds))</b><br/><i>follow‐up: mean 4 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 48.23 higher<br/>(24.75 lower to 121.2 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>f</sup><sup>,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of coenzyme Q10 on exercise capacity.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b><br/><i>follow‐up: mean 16 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.70<br/>(0.45 to 1.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>568<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup><sup>,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The results for adverse events associated with coenzyme Q10 are inconclusive.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000<br/>(71 to 174) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval;<b> MD</b> : mean difference; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty.</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty.</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty.</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty.</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to indirectness. The findings are applicable only to the characteristics of participants and dosing regimen as included in this one study. <br/><sup>b</sup>Downgraded by one level due to imprecision. The effect size has a very wide confidence interval that includes the possibilities of substantial harm, no difference, and a lower risk with coenzyme Q10. <br/><sup>c</sup>Downgraded by one level due to risk of bias. The included study that contributed most weight to the analysis had unclear risk for selection, detection, and reporting biases, and high risk for attrition bias. <br/><sup>d</sup>Downgraded by one level due to imprecision. The effect size has a very wide confidence interval that includes the possibility of only a minimal benefit with coenzyme Q10. <br/><sup>e</sup>Downgraded by two levels due to substantial risk of bias. Within the 7 included studies, selection bias was unclear in 6, performance bias was high in 1, detection bias was unclear in 3 and high in 1, attrition bias was high in 4, reporting bias was unclear in 3 and high in 1, and other bias was high in 1. <br/><sup>f</sup>Downgraded by two levels for imprecision. The effect size has a very wide confidence interval that includes the possibility of substantial harm, no difference, and a lower risk with coenzyme Q10. Also, the sample size is small. <br/><sup>g</sup>Downgraded by one level due to risk of bias. The 3 included studies had unclear risk of selection and detection biases, and high risk of attrition bias. Two of them also had unclear risk of reporting bias. <br/><sup>h</sup>Downgraded by one level due to indirectness. The findings are applicable only to the characteristics of participants and dosing regimen as included in the study that contributed the most weight to this analysis. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008684-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008684-sec-0009"></div> <section id="CD008684-sec-0010"> <h3 class="title" id="CD008684-sec-0010">Description of the condition</h3> <p>Heart failure is a term used to describe the state that develops when the heart cannot maintain adequate cardiac output, or can do so only at the expense of an elevated filling pressure (<a href="./references#CD008684-bbs2-0074" title="BoonNA , ColledgeNR , WalkerBR , HunterJAA . Davidson's Principles and Practice of Medicine. 20th edition. Churchill Livingstone, 2006.">Boon 2006</a>; <a href="./references#CD008684-bbs2-0117" title="SavareseG , LundLH . Global public health burden of heart failure. Cardiac Failure Review2017;3(1):7.">Savarese 2017</a>). Heart failure may be acute or chronic, and can be caused by a variety of conditions, including ischaemic heart disease (coronary artery disease), hypertension, elevated blood pressure, diseases of the heart valves, cardiomyopathy, and congenital heart diseases (<a href="./references#CD008684-bbs2-0078" title="DrexlerH , HasenfussG . Physiology of the normal and failing heart. In: CrawfordMH , DiMarcoJP , PaulusWJ , editors(s). Cardiology. 2nd edition. Edinburgh: Mosby, 2004:829.">Drexler 2004</a>; <a href="./references#CD008684-bbs2-0090" title="HoKK , PinskyJL , KannelWB , LevyD . The epidemiology of heart failure: the Framingham study. Journal of the American College of Cardiology1993;22:6A-13A.">Ho 1993</a>; <a href="./references#CD008684-bbs2-0113" title="RichardsonP , McKennaW , BristowM , MaischB , MautnerB , O'ConnellJ , et al. Report of the 1995 Word Health Organization/International Society and Federation of Cardiology Task Force on the Definition and classification of cardiomyopathies. Circulation1996;93:841-2.">Richardson 1996</a>; <a href="./references#CD008684-bbs2-0121" title="TeerlinkJR , GoldhaberSZ , PrefferMA . An overview of contemporary etiologies of congestive heart failure. American Heart Journal1991;121:1852-3.">Teerlink 1991</a>). The most commonly used classification system to quantify the degree of heart failure‐associated functional limitation was first developed by the New York Heart Association (NYHA; (<a href="./references#CD008684-bbs2-0107" title="Criteria Committee, New York Heart Association. Diseases of the Heart and Blood Vessels: Nomenclature and Criteria for Diagnosis. 6th edition. Boston: Little, Brown and Co, 1964.">NYHA 1964</a>)). This system assigns people to one of four functional classes, depending on the degree of effort needed to elicit symptoms: </p> <p> <ul id="CD008684-list-0001"> <li> <p>class I <b>–</b> symptoms of heart failure only at activity levels that would limit normal individuals; </p> </li> <li> <p>class II <b>–</b> symptoms of heart failure with ordinary exertion; </p> </li> <li> <p>class III <b>–</b> symptoms of heart failure with less than ordinary exertion; </p> </li> <li> <p>class IV <b>–</b> symptoms of heart failure at rest. </p> </li> </ul> </p> <p>It is now appreciated that heart failure often occurs with preserved left ventricular systolic function (<a href="./references#CD008684-bbs2-0111" title="RedfieldMM . Heart failure with preserved ejection fraction. New England Journal of Medicine2016;375(19):1868-77.">Redfield 2016</a>). Various studies estimate that as many as 40% to 60% of people with heart failure have diastolic dysfunction, as defined by a preserved left ventricular ejection fraction (<a href="./references#CD008684-bbs2-0080" title="ElesberAA , RedfieldMM . Approach to patients with heart failure and normal ejection fraction. Mayo Clinic Proceedings2001;76(10):1047-52.">Elesber 2001</a>; <a href="./references#CD008684-bbs2-0083" title="GottdienerJS , McClellandRL , MarshallR , ShemanskiL , FurbergCD , KitzmanDW , et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Annals of Internal Medicine2002;137(8):631-9.">Gottdiener 2002</a>). Thus, heart failure can be classified as ejection fraction reduced, ejection fraction mid‐range, and ejection fraction preserved (<a href="./references#CD008684-bbs2-0108" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJG , CoatsAJ , et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal2016;37(27):2129-200.">Ponikowski 2016</a>). </p> <p>There are at least 26 million people who have heart failure worldwide (<a href="./references#CD008684-bbs2-0117" title="SavareseG , LundLH . Global public health burden of heart failure. Cardiac Failure Review2017;3(1):7.">Savarese 2017</a>). It is estimated that 6.2 million Americans older than 20 years of age had heart failure between 2013 and 2016, compared to 5.7 million between 2009 and 2012 (<a href="./references#CD008684-bbs2-0124" title="ViraniSS , AlonsoA , BenjaminEJ , BittencourtMS , CallawayCW , CarsonAP , et al. Heart disease and stroke statistics 2020 update: a report from the American Heart Association. Circulation2020;141(9):e139-596. [DOI: 10.1161/CIR.0000000000000757]">Virani 2020</a>). The prevalence of heart failure in the USA is expected to increase from 2.42% in 2012 to 2.97% in 2030 (<a href="./references#CD008684-bbs2-0124" title="ViraniSS , AlonsoA , BenjaminEJ , BittencourtMS , CallawayCW , CarsonAP , et al. Heart disease and stroke statistics 2020 update: a report from the American Heart Association. Circulation2020;141(9):e139-596. [DOI: 10.1161/CIR.0000000000000757]">Virani 2020</a>). </p> <p>Chronic heart failure is a common condition, and is one of the most frequent causes of disability and admission to hospital in older individuals (<a href="./references#CD008684-bbs2-0093" title="LippiG , Sanchis-GomarF . Global epidemiology and future trends of heart failure. AME Medical Journal2020;5(15):1-6. [DOI: 10.21037/amj.2020.03.03]">Lippi 2020</a>; <a href="./references#CD008684-bbs2-0117" title="SavareseG , LundLH . Global public health burden of heart failure. Cardiac Failure Review2017;3(1):7.">Savarese 2017</a>). The prevalence of heart failure increases with age, and is associated with high morbidity and mortality worldwide (<a href="./references#CD008684-bbs2-0114" title="Rodriguez-ArtalejoF , Banegas BanegasJR , Guallar-CastillonP . Epidemiology of heart failure [Epidemiologia de la insuficiencia cardiaca]. Revista Espanola de Cardiologia2004;57(2):163-70.">Rodriguez 2004</a>; <a href="./references#CD008684-bbs2-0117" title="SavareseG , LundLH . Global public health burden of heart failure. Cardiac Failure Review2017;3(1):7.">Savarese 2017</a>). Based on European data, the 12‐month all‐cause mortality rate was 17% of hospitalised people with stable heart disease, and 7% in ambulatory people with heart disease, despite major advances in drug treatments (<a href="./references#CD008684-bbs2-0108" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJG , CoatsAJ , et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal2016;37(27):2129-200.">Ponikowski 2016</a>). American data showed even higher mortality rates (<a href="./references#CD008684-bbs2-0124" title="ViraniSS , AlonsoA , BenjaminEJ , BittencourtMS , CallawayCW , CarsonAP , et al. Heart disease and stroke statistics 2020 update: a report from the American Heart Association. Circulation2020;141(9):e139-596. [DOI: 10.1161/CIR.0000000000000757]">Virani 2020</a>). </p> <p>People with chronic heart failure commonly experience a relapsing and remitting disease course, with periods of stability and episodes of decompensation that lead to worsening symptoms that necessitate hospitalisation. The clinical picture depends on the nature of the underlying heart disease, the type of heart failure that it has evoked, and the neural and endocrine changes that have developed (<a href="./references#CD008684-bbs2-0074" title="BoonNA , ColledgeNR , WalkerBR , HunterJAA . Davidson's Principles and Practice of Medicine. 20th edition. Churchill Livingstone, 2006.">Boon 2006</a>). </p> </section> <section id="CD008684-sec-0011"> <h3 class="title" id="CD008684-sec-0011">Description of the intervention</h3> <p>Coenzyme Q10, or ubiquinone, is a non‐prescription nutritional supplement. It is a fat‐soluble molecule that acts as an electron carrier in mitochondria, and as a coenzyme for mitochondrial enzymes (<a href="./references#CD008684-bbs2-0085" title="Gutierrez-MariscalFM , Yubero-SerranoEM , VillalbaJM , Lopez-MirandaJ . Coenzyme Q10: from bench to clinic in aging diseases, a translational review. Critical Reviews in Food Science and Nutrition2019;59(14):2240-57.">Gutierrez‐Mariscal 2019</a>; <a href="./references#CD008684-bbs2-0109" title="RaiznerAE . Coenzyme Q10. Methodist DeBakey Cardiovascular Journal2019;15(3):185.">Raizner 2019</a>). Coenzyme Q10 is obtained through both tissue synthesis and diet (<a href="./references#CD008684-bbs2-0109" title="RaiznerAE . Coenzyme Q10. Methodist DeBakey Cardiovascular Journal2019;15(3):185.">Raizner 2019</a>). Supplementary oral administration of coenzyme Q10 has been found to increase coenzyme Q10 levels in plasma, platelets, and white blood cells (<a href="./references#CD008684-bbs2-0105" title="NiklowitzP , SonnenscheinA , JanetzkyB , AndlerW , MenkeT . Enrichment of coenzyme Q10 in plasma and blood cells: defence against oxidative damage. International Journal of Biological Sciences2007;3(4):257-62.">Niklowitz 2007</a>). Absorption of dietary coenzyme Q10 is slow and limited because of its hydrophobicity and large molecular weight. Solubilised coenzyme Q10 formulations show enhanced bioavailability, with a Tmax (time to reach maximum concentration) of approximately six hours, and an elimination half‐life of approximately 33 hours. Oral preparations of coenzyme Q10 are used in human therapeutics (<a href="./references#CD008684-bbs2-0073" title="BhagavanHN , ChopraRK . Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion2007;7S:S78-88.">Bhagavan 2007</a>). </p> <p>Coenzyme Q10 is considered a cell membrane stabiliser, and thought to be useful in preventing atherosclerosis, abnormal protein synthesis, and age‐related degenerative diseases (<a href="./references#CD008684-bbs2-0097" title="MiglioreL , MolinuS , NaccaratiA , MancusoM , RocchiA , SicilianoG . Evaluation of cytogenetic and DNA damage in mitochondrial disease patients: effects of coenzyme Q10 therapy. Mutagenesis2004;19(1):43-9.">Migliore 2004</a>). Coenzyme Q10 deficiency may be associated with a multitude of diseases, as diverse as coronary artery disease and congestive heart failure, Parkinson's disease, diabetes, breast cancer, and hypertension (<a href="./references#CD008684-bbs2-0105" title="NiklowitzP , SonnenscheinA , JanetzkyB , AndlerW , MenkeT . Enrichment of coenzyme Q10 in plasma and blood cells: defence against oxidative damage. International Journal of Biological Sciences2007;3(4):257-62.">Niklowitz 2007</a>). </p> <p>Coenzyme Q10 appears to be generally safe, with no significant side effects. Potential adverse effects include abdominal discomfort, headache, nausea, vomiting, and allergic maculopapular rash (<a href="./references#CD008684-bbs2-0070" title="BaggioE , GandiniR , PlancherAC , PasseriM , CarmosinoG . Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. Molecular Aspects of Medicine1994;15:s287-94.">Baggio 1994</a>; <a href="./references#CD008684-bbs2-0118" title="SinghRB , NiazMA , RastogiSS , ShuklaPK , ThakurAS . Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension1999;13(2):203-8.">Singh 1999</a>). Coenzyme Q10 may reduce the effectiveness of warfarin, and may limit or prevent effective anticoagulation (<a href="./references#CD008684-bbs2-0086" title="HeckAM , DeWittBA , LukesAL . Potential interactions between alternative therapies and warfarin. American Journal of Health-system Pharmacy2000;57(13):1221-7.">Heck 2000</a>). </p> <p>Some drugs can cause depletion of coenzyme Q10, such as statins (<a href="./references#CD008684-bbs2-0072" title="BertholdHK , NainiA , Di MauroS , HallikainenM , GyllingH , KroneW , et al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Safety2006;29(8):703-12.">Berthold 2006</a>; <a href="./references#CD008684-bbs2-0081" title="FolkersK , LangsjoenP , WillisR , RichardsonP , XiaLJ , YeCQ , et al. Lovastatin decreases coenzyme Q levels in humans. Proceedings of the National Academy of Sciences of the United States of America1990;87(22):8931-4.">Folkers 1990</a>; <a href="./references#CD008684-bbs2-0104" title="MortensenSA , LethA , AgnerE , RohdeM . Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Molecular Aspects of Medicine1997;18(Suppl):S137-44.">Mortensen 1997</a>), and beta‐blockers (<a href="./references#CD008684-bbs2-0091" title="KishiT , WatanabeT , FolkersK . Bioenergetics in clinical medicine XV. Inhibition of coenzyme Q10 enzymes by clinically used adrenergic blockers of beta-receptors. Research Communications in Chemical Pathology and Pharmacology1977;17(1):157-64.">Kishi 1977</a>). </p> </section> <section id="CD008684-sec-0012"> <h3 class="title" id="CD008684-sec-0012">How the intervention might work</h3> <p>Emerging data suggest that oxidative stress is increased in people with heart failure, and may predict outcome. Markers of oxidative stress have been shown to be elevated in people with both ischaemic and non‐ischaemic cardiomyopathy (<a href="./references#CD008684-bbs2-0095" title="McMurrayJ , McLayJ , ChopraM , BridgesA , BelchJJ . Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease. American Journal of Cardiology1990;65(18):1261-2.">McMurray 1990</a>; <a href="./references#CD008684-bbs2-0096" title="McMurrayJ , ChopraM , AbdullahI , SmithWE , DargieHJ . Evidence of oxidative stress in chronic heart failure in humans. European Heart Journal1993;14(11):1493-8.">McMurray 1993</a>), to be inversely correlated with the left ventricular ejection fraction (<a href="./references#CD008684-bbs2-0071" title="BelchJJ , BridgesAB , ScottN , ChopraM . Oxygen free radicals and congestive heart failure. British Heart Journal1991;65(5):245-8.">Belch 1991</a>), and directly correlated with the chronicity and severity of heart failure (<a href="./references#CD008684-bbs2-0077" title="Diaz-VelezCR , Garcia-CastineirasS , Mendoza-RamosE , Hernandez-LopezE . Increased malondialdehyde in peripheral blood of patients with congestive heart failure. American Heart Journal1996;131(1):146-52.">Diaz‐Velez 1996</a>; <a href="./references#CD008684-bbs2-0106" title="NishiyamaY , IkedaH , HaramakiN , YoshidaN , ImaizumiT . Oxidative stress is related to exercise intolerance in patients with heart failure. American Heart Journal1998;135(1):115-20.">Nishiyama 1998</a>), and to predict mortality in people with heart failure (<a href="./references#CD008684-bbs2-0123" title="TsutsuiT , TsutamotoT , WadaA , MaedaK , MabuchiN , HayashiM , et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. Journal of the American College of Cardiology2002;39(6):957-62.">Tsutsui 2002</a>). Coenzyme Q10 may reduce oxidative stress because of its antioxidant activity (<a href="./references#CD008684-bbs2-0110" title="RauchovaH , DrahotaZ , LenazG . Function of coenzyme Q in the cell: some biochemical and physiological properties. Physiological Research1995;44(4):209-16.">Rauchova 1995</a>), which has been shown to be similar to that of vitamin E (<a href="./references#CD008684-bbs2-0120" title="TappelAL . Vitamin E and free radical peroxidation of lipids. Annals of The New York Academy of Sciences1972;203:12-21.">Tappel 1972</a>). In addition, Coenzyme Q10 supplementation in animal models ameliorated left ventricular dysfunction, decreased left ventricular fibrosis, and improved endothelial function by enhancing nitric oxide bioavailability (<a href="./references#CD008684-bbs2-0076" title="De BlasioMJ , HuynhK , QinC , RosliS , KiriazisH , AyerA , et al. Therapeutic targeting of oxidative stress with coenzyme Q10 counteracts exaggerated diabetic cardiomyopathy in a mouse model of diabetes with diminished PI3K (p110α) signaling. Free Radical Biology and Medicine2015;87:137-47.">De Blasio 2015</a>; <a href="./references#CD008684-bbs2-0122" title="TsaiKL , HuangYH , KaoCL , YangDM , LeeHC , ChouHY , et al. A novel mechanism of coenzyme Q10 protects against human endothelial cells from oxidative stress-induced injury by modulating NO-related pathways. Journal of Nutritional Biochemistry2012;23(5):458-68.">Tsai 2012</a>). </p> <p>Besides preventing oxidative stress in heart failure, coenzyme Q10 may also have a role in stabilising myocardial calcium‐dependent ion channels, and in preventing the consumption of metabolites essential for adenosine‐5'‐triphosphate (ATP) synthesis (<a href="./references#CD008684-bbs2-0084" title="GreenbergS , FrishmanWH . Co-enzyme Q10: a new drug for cardiovascular disease. Journal of Clinical Pharmacology1990;30(7):596-608.">Greenberg 1990</a>). Plasma concentration of coenzyme Q10 was found to be an independent predictor of mortality in a cohort of participants with congestive heart failure (<a href="./references#CD008684-bbs2-0100" title="MolyneuxSL , FlorkowskiCM , GeorgePM , PilbrowAP , FramptonCM , LeverM ,  et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. Journal of the American College of Cardiology2008;52(18):1435-41.">Molyneux 2008</a>). Moreover, coenzyme Q10 myocardial tissue levels in people with chronic heart failure, are on average 33% lower than in a control population (<a href="./references#CD008684-bbs2-0102" title="MortensenSA , VadhanavikitS , MuratsuK , FolkersK . Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. International Journal of Tissue Reactions1990;12(3):155-62.">Mortensen 1990</a>; <a href="./references#CD008684-bbs2-0103" title="MortensenSA . Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone). Clinical Investigator1993;71(8 Suppl):S116-23.">Mortensen 1993</a>). The severity of heart failure correlates with the severity of coenzyme Q10 deficiency (<a href="./references#CD008684-bbs2-0101" title="MortensenSA , VadhanavikitS , FolkersK . Deficiency of coenzyme Q10 in myocardial failure. Drugs under Experimental and Clinical Research1984;X(7):497-502.">Mortensen 1984</a>). Therefore, supplementing this deficiency may play a role in the treatment of heart failure. </p> </section> <section id="CD008684-sec-0013"> <h3 class="title" id="CD008684-sec-0013">Why it is important to do this review</h3> <p>Despite the suggested potential benefits, the quality of evidence for the use of coenzyme Q10 in the treatment of heart failure has not been determined, and it is not included in American or European management guidelines for heart failure (<a href="./references#CD008684-bbs2-0108" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJG , CoatsAJ , et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal2016;37(27):2129-200.">Ponikowski 2016</a>; <a href="./references#CD008684-bbs2-0125" title="YancyCW , JessupM , BozkurtB , ButlerJ , CaseyDE , ColvinMM , et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation2017;136(6):e137-61. [DOI: 10.1161/CIR.0000000000000509]">Yancy 2017</a>). This review is important because it summarises the best available evidence for the safety and efficacy of coenzyme Q10 in people with heart failure. The information derived from this review could assist clinicians and heart associations to determine whether to recommend coenzyme Q10 for heart failure. </p> <p>An updated review to add new published trials and GRADE analysis is needed to reassess the safety and effectiveness of coenzyme Q10 in heart failure. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008684-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008684-sec-0014"></div> <p>To review the safety and efficacy of coenzyme Q10 in heart failure.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008684-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008684-sec-0015"></div> <section id="CD008684-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008684-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included all randomised controlled trials (RCT) that assessed the beneficial and harmful effects of coenzyme Q10 in heart failure. Cluster‐randomised clinical trials (cRCTs) were eligible for inclusion. We placed no restrictions on blinding, publication status, abstracts, conference proceedings, or language. We excluded quasi‐randomised and observational studies. When we identified cross‐over studies, we only considered data from the first phase. When first‐phase data were not available, we contacted the authors to obtain these data, if possible. </p> </section> <section id="CD008684-sec-0018"> <h4 class="title">Types of participants</h4> <p> <ul id="CD008684-list-0002"> <li> <p>We included all participants, regardless of age, with chronic heart failure, defined as a clinical syndrome characterised by breathlessness and fatigue, which was caused by an inability of the heart to support adequate circulation, which may limit exercise tolerance, and may lead to pulmonary congestion and peripheral oedema; also, if possible, defined by more objective evidence of left ventricular systolic or diastolic function (e.g. echocardiography, radionuclide ventriculography, cardiac magnetic resonance, cardiac catheterization, and biomarkers, such as brain natriuretic peptide (BNP), and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP). </p> </li> <li> <p>We included participants with ejection fraction reduced heart failure, ejection fraction mid‐range heart failure, and ejection fraction preserved heart failure. </p> </li> <li> <p>We included participants with chronic heart failure of any severity.</p> </li> <li> <p>Chronic heart failure included left‐sided and right‐sided heart failure.</p> </li> <li> <p>We excluded participants with acute heart failure, defined as rapid onset or worsening of sign, symptoms, or both, of heart failure (<a href="./references#CD008684-bbs2-0108" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJG , CoatsAJ , et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal2016;37(27):2129-200.">Ponikowski 2016</a>). </p> </li> <li> <p>We included any studies in which the majority of participants met our inclusion criteria, We asked the trial authors for data for the subgroup of interest, and (if no data forthcoming) used sensitivity analysis to investigate the impact of including studies in which not all participants met the inclusion criteria. </p> </li> </ul> </p> </section> <section id="CD008684-sec-0019"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD008684-list-0003"> <li> <p>Coenzyme Q10 versus placebo</p> </li> <li> <p>Coenzyme Q10 versus another active agent for use in heart failure</p> </li> <li> <p>High‐dose versus low‐dose coenzyme Q10</p> </li> </ul> </p> </section> <section id="CD008684-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We used all outcome data from the longest follow‐up. We did not base our decision to include or exclude the study solely on the reporting of our outcomes of interest. When a published report did not appear to report one of these outcomes, we accessed the trial protocol and contacted the trial authors to ascertain whether the outcomes were measured but not reported. We included relevant trials, which measured these outcomes but did not report the data at all, or not in a usable format, in the review as part of the narrative. </p> <section id="CD008684-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008684-list-0004"> <li> <p>All‐cause mortality</p> </li> <li> <p>Cardiovascular (CV) mortality</p> </li> <li> <p>Fatal and non‐fatal myocardial infarction</p> </li> <li> <p>Fatal and non‐fatal stroke</p> </li> <li> <p>Revascularisation procedures (percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG)) </p> </li> <li> <p>Hospitalisation due to heart failure (number of people with at least one hospitalisation due to heart failure) </p> </li> <li> <p>All‐cause hospitalisation (number of people with at least one hospitalisation for any cause) </p> </li> <li> <p>New York Heart Association (NYHA) classification of clinical status (four classes, lower = better) </p> </li> </ul> </p> </section> <section id="CD008684-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008684-list-0005"> <li> <p>Left ventricular ejection fraction, determined by echocardiography, contrast, or radionuclide angiography </p> </li> <li> <p>Symptom improvement, measured by individual trials, by exercise capacity (exercise duration or walking distance, or both), or both </p> </li> <li> <p>Other exercise variables (peak VO₂, exercise haemodynamics)</p> </li> <li> <p>Quality of life</p> </li> <li> <p>BNP and NT‐pro BNP</p> </li> <li> <p>Measurement of post‐therapeutic serum levels of coenzyme Q10</p> </li> <li> <p>Adverse events (number of people with at least one adverse event)</p> </li> <li> <p>Cost‐effectiveness</p> </li> </ul> </p> </section> </section> </section> <section id="CD008684-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008684-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We updated the searches from 2013 on 16 October 2020. We searched the following databases:</p> <p> <ul id="CD008684-list-0006"> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL, 2020 Issue 10), in the Cochrane Library (searched 16 October 2020); </p> </li> <li> <p>Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE Daily and MEDLINE Ovid (1946 to 15 October 2020); </p> </li> <li> <p>Embase Ovid (1980 to 2020 week 41);</p> </li> <li> <p>Web of Science Clarivate Analytics (1900 to 16 October 2020);</p> </li> <li> <p>CINAHL Plus EBSCO (1981 to 16 October 2020);</p> </li> <li> <p>AMED Ovid (Allied and Complementary Medicine; 1985 to October 2020).</p> </li> </ul> </p> <p>We also searched the following clinical trials registers for ongoing or unpublished studies: </p> <p> <ul id="CD008684-list-0007"> <li> <p>International Standard Randomised Controlled Trial Number Registry (ISRCTN; <a href="https://www.isrctn.com/" target="_blank">www.isrctn.com/</a>; searched 11 November 2019); </p> </li> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>; searched 16 July 2020). </p> </li> </ul> </p> <p>The RCT filter for MEDLINE is the Cochrane sensitivity‐maximising RCT filter, and for Embase, we applied the terms recommended in the Cochrane <i>Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008684-bbs2-0092" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Lefebvre 2011</a>). For CINAHL, we used an adaptation of the Cochrane RCT filter. We applied no language restrictions. Searching the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) was not possible, as the database was not available. The search strategies are in <a href="./appendices#CD008684-sec-0092">Appendix 1</a>. </p> </section> <section id="CD008684-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the bibliographic references of the included randomised controlled trials to find randomised controlled trials not identified by the electronic searches. When possible, we approached the principal authors of the identified randomised controlled trials and enquired if they knew of any other randomised controlled trials. </p> </section> </section> <section id="CD008684-sec-0026"> <h3 class="title" id="CD008684-sec-0026">Data collection and analysis</h3> <p>We conducted the meta‐analyses according to Cochrane recommendations (<a href="./references#CD008684-bbs2-0089" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>), using Review Manager 5.4 (<a href="./references#CD008684-bbs2-0112" title="Review Manager 5 (RevMan 5). Version 5.4. The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> <section id="CD008684-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Five authors (KT, BS, AM, MK, MF) independently assessed the identified references to determine if they fulfilled the inclusion criteria (two authors per reference). First, we screened the references by title, abstract, or both, and excluded those which were clearly not relevant to the review. Then, we obtained the full texts for the references that passed the first screening phase, and evaluated them for inclusion. In cases when references did not have sufficient information to determine their eligibility, we contacted the trial authors, asking for more information; if we did not receive a response, we excluded these studies. We listed the excluded trials with the reasons for exclusion. We resolved disagreements by discussion. We summarised the flow of papers through the search and selection process using a PRISMA flow chart (<a href="#CD008684-fig-0001">Figure 1</a>; <a href="./references#CD008684-bbs2-0099" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ2009;339:B2535.">Moher 2009</a>). </p> <div class="figure" id="CD008684-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow chart" data-id="CD008684-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow chart</p> </div> </div> </div> </section> <section id="CD008684-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Five authors (KT, BS, AM, MK, MF) independently extracted data (two authors per trial), and resolved disagreements by discussion. We used a standardised data collection form to extract data on methods, participants, interventions, and outcomes. If we identified more than one publication on a single randomised controlled trial, we extracted the most appropriate data. </p> <p>We extracted data needed to assess risk of bias, conduct meta‐analysis, and investigate any possible heterogeneity. The extracted data included data about study methodology (design, duration, setting, inclusion and exclusion criteria, comparisons groups, randomisation, blinding), participants (total number, demographics, medical conditions), intervention (dose, route, preparation), control (placebo versus active compounds, dosing), outcomes (primary and secondary, outcome measures, time points measured), and funding. </p> </section> <section id="CD008684-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed methodological quality according to our level of confidence that the design and report of a published trial restricted bias in the intervention comparison (<a href="./references#CD008684-bbs2-0098" title="MoherD , PhamB , JonesA , CookDJ , JadadA , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analysis. Lancet1998;352:609-13.">Moher 1998</a>). In assessing the risk of bias, we used the Cochrane tool for assessing risk of bias, described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008684-bbs2-0088" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We assessed risk of bias in the following domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, selective reporting, and other biases. </p> </section> <section id="CD008684-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <section id="CD008684-sec-0031"> <h5 class="title">Dichotomous data</h5> <p>We reported absolute effect and risk ratios (RR), with 95% confidence intervals (CI). We calculated the the number needed to treat for an additional beneficial outcome (NNTB), and the number needed to treat for an additional harmful outcome (NNTH), if possible. </p> </section> <section id="CD008684-sec-0032"> <h5 class="title">Continuous data</h5> <p>We calculated mean differences (MD) with 95% CIs for outcomes reported with the same measure. If the quality of life outcome was reported using different tools in different studies, we had planned to use the standardized mean difference (SMD). </p> </section> </section> <section id="CD008684-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>When we retrieved cross‐over studies from the search, we only took the first arm into consideration. </p> <p>We used all outcome data from the longest follow‐up, as mentioned above.</p> <p>We used guidelines from the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> guidelines to inform the inclusion and analysis of cRCTs in our review (<a href="./references#CD008684-bbs2-0088" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). When analysing results from cRCTs, we had planned to adjust for clustering to avoid artificially narrow confidence intervals for the treatment effect. We also planned to estimate the intracluster correlation coefficient (ICC) to quantify the extent to which data from observations from the same cluster were correlated. However, we did not identify any relevant cluster‐randomised trials. </p> <p>We handled trials with more than one comparison (e.g. two doses of coenzyme Q10 versus placebo or coenzyme Q10 versus another treatment versus placebo), by splitting the shared group (placebo in the first example and coenzyme Q10 in the second) into two or more groups with smaller sample size, to enable us to include two or more comparisons. </p> </section> <section id="CD008684-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>We performed all analyses on an intention‐to‐treat basis, using the last reported observed response (carry forward) and including all participants, regardless of compliance or follow‐up. In addition, we planned to perform a 'worst‐case scenario' analysis, considering all participants with missing data as treatment failures. We used the Review Manager 5 calculator to calculate missing data, like standard deviation (<a href="./references#CD008684-bbs2-0112" title="Review Manager 5 (RevMan 5). Version 5.4. The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> </section> <section id="CD008684-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity using a Chi² test, and we used the I² statistic to quantify inconsistency across included studies (<a href="./references#CD008684-bbs2-0087" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>). We also assessed statistical heterogeneity by visually examining the graphical presentations (forest plots; (<a href="./references#CD008684-bbs2-0079" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315:629-34.">Egger 1997</a>)). </p> </section> <section id="CD008684-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>We tried to locate the protocol for each included randomised controlled trial. If the protocol was available, we compared its outcomes with those in the published RCT report. If it was not available, we compared the outcomes listed in the methods section of the report with the actual reported results. We planned to use a funnel plot of all included trials to check the presence of publication bias, but there were insufficient trials (<a href="./references#CD008684-bbs2-0079" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315:629-34.">Egger 1997</a>). </p> </section> <section id="CD008684-sec-0037"> <h4 class="title">Data synthesis</h4> <p>We undertook meta‐analysis when there were sufficient data of a suitable type, using Review Manager 5 (<a href="./references#CD008684-bbs2-0112" title="Review Manager 5 (RevMan 5). Version 5.4. The Cochrane Collaboration, 2020.">Review Manager 2020</a>). When there were too few clinically homogeneous trials for us to perform a meta‐analysis, we presented a narrative synthesis. </p> <p>We used the random‐effects model to avoid the risk that the variability between the studies may be exclusively due to a random sampling variation around a fixed effect. Using the random‐effects model is also recommended by <i>Clinical Evidence</i> (<a href="./references#CD008684-bbs2-0075" title="BMJ Clinical Evidence. EBM Tools: Glossary. clinicalevidence.bmj.com/ceweb/resources/glossary.jsp#Random_effects (accessed 16 January 2010).">Clinical Evidence</a>). </p> </section> <section id="CD008684-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In cases of significant heterogeneity, we aimed to address it by exploring clinical and methodological variations between the studies. If significant differences were identified, we conducted a subgroup analysis to offer new insights and confirm the effect in the different subgroups. Therefore, we conducted a posthoc subgroup analysis to compare studies without a maximum coenzyme Q10 dose against those with a maximum dose of 200 mg daily. Age and gender were the two subgroups planned for analysis in the protocol; however, we were unable to do so, due to insufficient data. </p> </section> <section id="CD008684-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We did not carry out any sensitivity analysis because of the small number of included studies for each outcome. </p> </section> <section id="CD008684-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach to assess the quality of the evidence (<a href="./references#CD008684-bbs2-0089" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>), and GRADEpro GDT (<a href="http://gradepro.org" target="_blank">gradepro.org</a>), to import data from Review Manager 5 (<a href="./references#CD008684-bbs2-0112" title="Review Manager 5 (RevMan 5). Version 5.4. The Cochrane Collaboration, 2020.">Review Manager 2020</a>), to create a ’Summary of findings’ table. This table provides outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to the care of people with the disorder and decision‐making. We selected the following main outcomes for the ’Summary of findings’ table: </p> <p> <ol id="CD008684-list-0008"> <li> <p>All‐cause mortality</p> </li> <li> <p>Fatal and non‐fatal myocardial infarction</p> </li> <li> <p>Fatal and non‐fatal stroke</p> </li> <li> <p>Hospitalisation due to heart failure</p> </li> <li> <p>Left ventricular ejection fraction</p> </li> <li> <p>Exercise capacity, measured by treadmill exercise test duration</p> </li> <li> <p>Adverse events</p> </li> </ol> </p> <p>Although important, we did not include NYHA clinical status as available data were exhaustive and non‐combinable. We intended to include three comparisons (coenzyme Q10 versus placebo or no coenzyme Q10, coenzyme Q10 versus another active agent, and high dose versus low dose coenzyme Q10). However, the identified studies only compared coenzyme Q10 to placebo or standard care, thus, we only created one, instead of three, 'Summary of findings' table. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008684-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008684-sec-0041"></div> <section id="CD008684-sec-0042"> <h3 class="title">Description of studies</h3> <section id="CD008684-sec-0043"> <h4 class="title">Results of the search</h4> <p>The search and screening in the original review resulted in seven included studies. After reviewing these seven studies, we found that one study did not meet the inclusion criteria, so we excluded it (<a href="./references#CD008684-bbs2-0012" title="AdarshK , KaurH , MohanV . Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). BioFactors (Oxford, England)2008;32(1-4):145-9. ">Adarsh 2008</a>). </p> <p>For the update, the initial database search on 16 October 2020 yielded 694 records. We also identified 14 records from other sources (one reference was identified by checking the bibliographic references of the included RCTs; 13 references identified by searching the clinical trials databases). After de‐duplication, there were 547 references for screening. We removed 505 records (we excluded 495 references by their title and abstract; 5 references were already included in the original review; 1 reference was an additional report for a study in the original review; we identified 4 further duplicate references). Of the 42 remaining references, we combined those belonging to the same study, resulting in 28 unique studies. We retrieved and examined the full texts for the 28 studies, and excluded 14 studies. For seven studies, we needed usable data and additional information, so we contacted the study authors. However, we did not get a response from the authors, so we excluded these seven studies. Of the seven remaining studies, two studies were ongoing (confirmed by contacting their authors). As a result, we identified five new studies with the updated search. </p> <p>Including the six studies from the original review, the updated review includes a total of 11 studies. Please refer to the PRISMA flow chart for details on the updated search (<a href="#CD008684-fig-0001">Figure 1</a>). </p> </section> <section id="CD008684-sec-0044"> <h4 class="title">Included studies</h4> <p>This review included 11 randomised controlled trials (RCT) with 1573 participants. Only four studies had relatively large sample sizes (128 in <a href="./references#CD008684-bbs2-0011" title="QingyanZ , OkelloE , YanhongT , BingW , CongxinH . Effect of coenzyme Q10 administration on the incidence of atrial fibrillation in patients with heart failure. Circulation2010;122(2):e209. ZhaoQ , KebbatiAH , ZhangY , TangY , OkelloE , HuangC . Effect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure. Journal of Investigative Medicine2015;63(5):735-9. ">Zhao 2015</a>; 148 in <a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>; 420 in <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>; 641 in <a href="./references#CD008684-bbs2-0007" title="MoriscoC , TrimarcoB , CondorelliM . Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clinical Investigator1993;71(8 Suppl):S134-6. ">Morisco 1993</a>). Sample sizes for the rest of the studies ranged from 20 to 55 participants. Only one study had a cross‐over design (from which only first phase data were used; (<a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>)). All other studies had a parallel design. </p> <p>Five studies were conducted in Asia (<a href="./references#CD008684-bbs2-0001" title="BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(10):A26. BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(5):295-9. ">Berman 2004</a>; <a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>; <a href="./references#CD008684-bbs2-0005" title="KocharianA , ShabanianR , Rafiei-KhorgamiM , KianiA , Heidari-BateniG , Kocharian Armen, et al. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiology in the Young2009;19(5):501-6. NCT02115581. Coenzyme Q10 supplementation in children with idiopathic dilated cardiomyopathy. clinicaltrials.gov/show/nct02115581 (first posted 16 April 2014). ">Kocharian 2009</a>; <a href="./references#CD008684-bbs2-0010" title="ISRCTN96610559. Coenzyme Q10 supplementation in heart failure with preserved ejection fraction patients. www.isrctn.com/ISRCTN96610559 (date assigned 2 March 2018). SobirinMA , HerryY , SofiaSN , UddinI , RifqiS , TsutsuiH . Effects of coenzyme Q10 supplementation on diastolic function in patients with heart failure with preserved ejection fraction. Drug Discoveries &amp; Therapeutics2019;13(1):38-46. ">Sobirin 2019</a>; <a href="./references#CD008684-bbs2-0011" title="QingyanZ , OkelloE , YanhongT , BingW , CongxinH . Effect of coenzyme Q10 administration on the incidence of atrial fibrillation in patients with heart failure. Circulation2010;122(2):e209. ZhaoQ , KebbatiAH , ZhangY , TangY , OkelloE , HuangC . Effect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure. Journal of Investigative Medicine2015;63(5):735-9. ">Zhao 2015</a>), two studies in Europe (<a href="./references#CD008684-bbs2-0007" title="MoriscoC , TrimarcoB , CondorelliM . Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clinical Investigator1993;71(8 Suppl):S134-6. ">Morisco 1993</a>; <a href="./references#CD008684-bbs2-0009" title="MunkholmH , HansenHH , RasmussenK . Coenzyme Q10 treatment in serious heart failure. Biofactors1999;9(2-4):285-9. ">Munkholm 1999</a>), one study in Russia (<a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>), one in Australia (<a href="./references#CD008684-bbs2-0003" title="KeoghA , FentonS , LeslieC , AboyounC , MacdonaldP , ZhaoYC , et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation2003;12(3):135-41. ">Keogh 2003</a>), and one in the USA (<a href="./references#CD008684-bbs2-0004" title="KhattaM , AlexanderBS , KrichtenCM , FisherML , FreudenbergerR , RobinsonSW , et al. The effect of coenzyme Q10 in patients with congestive heart failure. Annals of Internal Medicine2000;132(8):636-40. ">Khatta 2000</a>). One study enrolled participants from Europe, Australia, and Asia (<a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>). </p> <p>All studies were conducted with adults, except <a href="./references#CD008684-bbs2-0005" title="KocharianA , ShabanianR , Rafiei-KhorgamiM , KianiA , Heidari-BateniG , Kocharian Armen, et al. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiology in the Young2009;19(5):501-6. NCT02115581. Coenzyme Q10 supplementation in children with idiopathic dilated cardiomyopathy. clinicaltrials.gov/show/nct02115581 (first posted 16 April 2014). ">Kocharian 2009</a>, which included participants younger than 18 years. In addition, all studies used placebo plus conventional therapy in the control group except for two studies, which used conventional therapy alone (<a href="./references#CD008684-bbs2-0010" title="ISRCTN96610559. Coenzyme Q10 supplementation in heart failure with preserved ejection fraction patients. www.isrctn.com/ISRCTN96610559 (date assigned 2 March 2018). SobirinMA , HerryY , SofiaSN , UddinI , RifqiS , TsutsuiH . Effects of coenzyme Q10 supplementation on diastolic function in patients with heart failure with preserved ejection fraction. Drug Discoveries &amp; Therapeutics2019;13(1):38-46. ">Sobirin 2019</a>; <a href="./references#CD008684-bbs2-0011" title="QingyanZ , OkelloE , YanhongT , BingW , CongxinH . Effect of coenzyme Q10 administration on the incidence of atrial fibrillation in patients with heart failure. Circulation2010;122(2):e209. ZhaoQ , KebbatiAH , ZhangY , TangY , OkelloE , HuangC . Effect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure. Journal of Investigative Medicine2015;63(5):735-9. ">Zhao 2015</a>). </p> <p>The daily dose of coenzyme Q10 varied significantly among studies: 30 mg in <a href="./references#CD008684-bbs2-0011" title="QingyanZ , OkelloE , YanhongT , BingW , CongxinH . Effect of coenzyme Q10 administration on the incidence of atrial fibrillation in patients with heart failure. Circulation2010;122(2):e209. ZhaoQ , KebbatiAH , ZhangY , TangY , OkelloE , HuangC . Effect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure. Journal of Investigative Medicine2015;63(5):735-9. ">Zhao 2015</a>; 60 mg in <a href="./references#CD008684-bbs2-0001" title="BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(10):A26. BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(5):295-9. ">Berman 2004</a>; 150 mg in <a href="./references#CD008684-bbs2-0003" title="KeoghA , FentonS , LeslieC , AboyounC , MacdonaldP , ZhaoYC , et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation2003;12(3):135-41. ">Keogh 2003</a>; 200 mg in <a href="./references#CD008684-bbs2-0004" title="KhattaM , AlexanderBS , KrichtenCM , FisherML , FreudenbergerR , RobinsonSW , et al. The effect of coenzyme Q10 in patients with congestive heart failure. Annals of Internal Medicine2000;132(8):636-40. ">Khatta 2000</a> and <a href="./references#CD008684-bbs2-0009" title="MunkholmH , HansenHH , RasmussenK . Coenzyme Q10 treatment in serious heart failure. Biofactors1999;9(2-4):285-9. ">Munkholm 1999</a>; 225 mg in <a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>; 300 mg in <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a> and <a href="./references#CD008684-bbs2-0010" title="ISRCTN96610559. Coenzyme Q10 supplementation in heart failure with preserved ejection fraction patients. www.isrctn.com/ISRCTN96610559 (date assigned 2 March 2018). SobirinMA , HerryY , SofiaSN , UddinI , RifqiS , TsutsuiH . Effects of coenzyme Q10 supplementation on diastolic function in patients with heart failure with preserved ejection fraction. Drug Discoveries &amp; Therapeutics2019;13(1):38-46. ">Sobirin 2019</a>; and 400 mg in <a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>. In <a href="./references#CD008684-bbs2-0005" title="KocharianA , ShabanianR , Rafiei-KhorgamiM , KianiA , Heidari-BateniG , Kocharian Armen, et al. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiology in the Young2009;19(5):501-6. NCT02115581. Coenzyme Q10 supplementation in children with idiopathic dilated cardiomyopathy. clinicaltrials.gov/show/nct02115581 (first posted 16 April 2014). ">Kocharian 2009</a> and <a href="./references#CD008684-bbs2-0007" title="MoriscoC , TrimarcoB , CondorelliM . Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clinical Investigator1993;71(8 Suppl):S134-6. ">Morisco 1993</a>, participants received 2 mg/kg of coenzyme Q10 daily. In one study, coenzyme Q10 was given in a nasal drop form (<a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>). In all other included studies, it was given orally. </p> <p>The follow‐up period varied among studies: one month in <a href="./references#CD008684-bbs2-0010" title="ISRCTN96610559. Coenzyme Q10 supplementation in heart failure with preserved ejection fraction patients. www.isrctn.com/ISRCTN96610559 (date assigned 2 March 2018). SobirinMA , HerryY , SofiaSN , UddinI , RifqiS , TsutsuiH . Effects of coenzyme Q10 supplementation on diastolic function in patients with heart failure with preserved ejection fraction. Drug Discoveries &amp; Therapeutics2019;13(1):38-46. ">Sobirin 2019</a>; three months in <a href="./references#CD008684-bbs2-0001" title="BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(10):A26. BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(5):295-9. ">Berman 2004</a>, <a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>, <a href="./references#CD008684-bbs2-0003" title="KeoghA , FentonS , LeslieC , AboyounC , MacdonaldP , ZhaoYC , et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation2003;12(3):135-41. ">Keogh 2003</a> and <a href="./references#CD008684-bbs2-0009" title="MunkholmH , HansenHH , RasmussenK . Coenzyme Q10 treatment in serious heart failure. Biofactors1999;9(2-4):285-9. ">Munkholm 1999</a>; and six months in <a href="./references#CD008684-bbs2-0004" title="KhattaM , AlexanderBS , KrichtenCM , FisherML , FreudenbergerR , RobinsonSW , et al. The effect of coenzyme Q10 in patients with congestive heart failure. Annals of Internal Medicine2000;132(8):636-40. ">Khatta 2000</a>, <a href="./references#CD008684-bbs2-0005" title="KocharianA , ShabanianR , Rafiei-KhorgamiM , KianiA , Heidari-BateniG , Kocharian Armen, et al. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiology in the Young2009;19(5):501-6. NCT02115581. Coenzyme Q10 supplementation in children with idiopathic dilated cardiomyopathy. clinicaltrials.gov/show/nct02115581 (first posted 16 April 2014). ">Kocharian 2009</a> and <a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>. <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a> reported data at 4 and 26 months, while <a href="./references#CD008684-bbs2-0011" title="QingyanZ , OkelloE , YanhongT , BingW , CongxinH . Effect of coenzyme Q10 administration on the incidence of atrial fibrillation in patients with heart failure. Circulation2010;122(2):e209. ZhaoQ , KebbatiAH , ZhangY , TangY , OkelloE , HuangC . Effect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure. Journal of Investigative Medicine2015;63(5):735-9. ">Zhao 2015</a> reported data at 6 and 12 months. <a href="./references#CD008684-bbs2-0007" title="MoriscoC , TrimarcoB , CondorelliM . Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clinical Investigator1993;71(8 Suppl):S134-6. ">Morisco 1993</a> followed participants up to 12 months. </p> <p>Two studies were partially funded by pharmaceutical companies that manufacture and distribute coenzyme Q10 supplements (<a href="./references#CD008684-bbs2-0003" title="KeoghA , FentonS , LeslieC , AboyounC , MacdonaldP , ZhaoYC , et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation2003;12(3):135-41. ">Keogh 2003</a>; <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>). </p> <p>See <a href="./references#CD008684-sec-0102" title="">Characteristics of included studies</a>. </p> </section> <section id="CD008684-sec-0045"> <h4 class="title">Excluded studies</h4> <p>In the original review, out of the 721 papers identified in the search, we excluded 567 early in the selection process because the title was irrelevant to the main area of interest. Of the remaining papers, 139 did not meet one or more of the inclusion criteria. We excluded randomised controlled studies with a cross‐over design (which were identified in the original review) later, as their data were unsuitable for analysis. </p> <p>In the update, we excluded 505 out of 547 references by title, abstract, or both, as they were clearly irrelevant to our review. After combining references belonging to the same study, and assessing the full text, we excluded 14 studies: five studies excluded people with heart failure (<a href="./references#CD008684-bbs2-0022" title="FedackoJ , PellaD , RybarR . Influence of coenzyme Q10 supplementation in statin treated patients on left ventricular diastolic dysfunction. Results of randomised double-blind clinical study. European Heart Journal2009;30:369-70. ">Fedacko 2009</a>; <a href="./references#CD008684-bbs2-0026" title="IRCT2015070223018N1. Effect of Q10 coenzyme in improving cardiac function. en.irct.ir/trial/19746 (date registered 11 August 2015). ">IRCT2015070223018N1</a>; <a href="./references#CD008684-bbs2-0053" title="NCT03586414. MitoQ supplementation and cardiovascular function in healthy men and women. clinicaltrials.gov/show/nct03586414 (first posted 13 July 2018). ">NCT03586414</a>; <a href="./references#CD008684-bbs2-0059" title="RiveraMB , YeungCK , Robinson-CohenC , PhillipsBR , RuzinskiJ , RockD , et al. Effect of coenzyme Q10 on biomarkers of oxidative stress and cardiac function in hemodialysis patients: the CoQ10 biomarker trial. American Journal of Kidney Diseases2017;69(3):389-99. ">Rivera 2017</a>; <a href="./references#CD008684-bbs2-0065" title="TurkS , BakiA , SolakY , KayrakM , AtalayH , GaipovA , et al. Coenzyme Q10 supplementation and diastolic heart functions in hemodialysis patients: a randomized double-blind placebo-controlled trial. Hemodialysis International2013;17(3):374-81. ">Turk 2013</a>), four studies were not RCTs (<a href="./references#CD008684-bbs2-0018" title="YuanyuanC , GuozhenS , XiaoranM . Research progress on correlation and intervention of micronutrients and chronic heart failure. Chinese Nursing Research2017;31(34):4334-7. ">Chen 2017</a>; <a href="./references#CD008684-bbs2-0019" title="ChenFL , ChangPS , LinYC , LinPT . A pilot clinical study of liquid ubiquinol supplementation on cardiac function in pediatric dilated cardiomyopathy. Nutrients2018;10(11):07. ">Chen 2018</a>; <a href="./references#CD008684-bbs2-0031" title="JPRN-UMIN000020203. Study of a heart failure treatment using a combination drug consisting of reduced coenzyme Q10, astaxanthin, citrulline, and zinc. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000020203 (date registered 15 December 2015). ">JPRN‐UMIN000020203</a>; <a href="./references#CD008684-bbs2-0050" title="MiyazakiT , ShimizuM , TakagiA , KatoT , SudaS , HikiM , et al. Coenzyme Q10 levels are associated with occurrence of cardiogenic shock and in-hospital death in patients admitted to coronary care unit. Circulation2013;128(22):Abstract 17490. ">Miyazaki 2013</a>), two studies investigated coenzyme Q10 combined with other active agents (<a href="./references#CD008684-bbs2-0029" title="JohanssonP , DahlstromO , DahlstromU , AlehagenU . Effect of selenium and Q10 on the cardiac biomarker NT-proBNP. Scandinavian Cardiovascular Journal2013;47(5):281-8. JohanssonP , DahlstromO , DahlstromU , AlehagenU . Improved health-related quality of life, and more days out of hospital with supplementation with selenium and coenzyme Q10 combined. Results from a double blind, placebo-controlled prospective study. Journal of Nutrition Health &amp; Aging2015;19(9):870-7. ">Johansson 2013</a>; <a href="./references#CD008684-bbs2-0058" title="NCT01925937. Atorvastatin/coenzymeQ10 in congestive heart failure. clinicaltrials.gov/show/nct01925937 (first posted 20 August 2013). PourmoghaddasM , RabbaniM , ShahabiJ , GarakyaraghiM , KhanjaniR , HedayatP . Combination of atorvastatin/coenzyme Q10 as adjunctive treatment in congestive heart failure: a double-blind randomized placebo-controlled clinical trial. Arya Atherosclerosis2014;10(1):1-5. ">Pourmoghaddas 2014</a>), two studies did not investigate supplemental coenzyme Q10 (<a href="./references#CD008684-bbs2-0030" title="JPRN-UMIN000007695. Comparison of effects of pitavastatin and rosuvastatin on patients with chronic heart failure. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000007695 (date of disclosure 10 April 2012). ">JPRN‐UMIN000007695</a>; <a href="./references#CD008684-bbs2-0049" title="McMurrayJJV , KjekshusJ , DunselmanP , HjalmarsonA , WedelH , LindbergM , et al. Prognostic importance of co-enzyme Q10 in heart failure and interaction with statin therapy in the controlled rosuvastatin Mmltinational trial in heart failure trial (CORONA). European Heart Journal2009;30:1027. ">McMurray 2009</a>), and one study met the inclusion criteria but was terminated early and had no available results (<a href="./references#CD008684-bbs2-0032" title="JPRN-UMIN000027248. Effects of reduced form of coenzyme Q10 (ubiquinol) on heart failure and arrhythmias. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000027248 (date of registration 1 October 2017). ">JPRN‐UMIN000027248</a>). We excluded seven more studies, as they had no usable data and their authors did not respond to our queries (<a href="./references#CD008684-bbs2-0034" title="KukharchikG , SichinavaL , BurbelloA , YubrinaI , GaykovayaL , SorokinL , et al. Analysis of changes of ECHO-cardiogram indices in patients with chronic heart failure during therapy with coenzyme Q10. European Journal of Heart Failure2016;18:109. ">Kukharchik 2016</a>; <a href="./references#CD008684-bbs2-0035" title="KukharchikG , SichinavaL , GaykovayaL , BurbelloA , YubrinaI , SorokinL . Some aspects of the effect of coenzyme Q10 on inflammatory processes, remodeling and functional status of endothelium in chronic heart failure. European Journal of Heart Failure2016;18:399. ">Kukharchik 2016a</a>; <a href="./references#CD008684-bbs2-0036" title="KukharchikG , LobanovaO , SichinavaL , GaikovayaL , ErmakovA . The effect of coenzyme Q10 on the content of proinflammatory makers and the realization of the mitochondrial mechanism of apoptosis in chronic heart failure. Journal of the American College of Cardiology2017;70(16):C145. ">Kukharchik 2017</a>; <a href="./references#CD008684-bbs2-0038" title="KumarA , MohanV , HarharpreetK . Coenzyme Q10 as an adjuvant therapy in heart failure (HF). Cardiology2015;131:345. ">Kumar 2015</a>; <a href="./references#CD008684-bbs2-0046" title="Leonova IA , BolduevaS , KuharchikG , SichinavaL , GaykovayaL . Changing of some markers of inflammation and remodeling in post-infarction patients with chronic heart failure after ubidecarenone treatment. European Journal of Heart Failure2018;20(Suppl 1):82-3. ">Leonova 2018</a>; <a href="./references#CD008684-bbs2-0055" title="MedvedevO , TokarevaOG , GorodetskayaEA , KalenikovaEI , SizovaZM . CoQ10 treatment of patients with CHF and effects of BNP level. European Journal of Heart Failure2016;18:107. ">Oleg 2016</a>; <a href="./references#CD008684-bbs2-0061" title="SaurabhS , YadavA , TiwariRK , SharmaA , GoyalYK , JainA . Comparative study of Ubiquinone (CoQ10) and Krill oil in dilated cardiomyopathy. Indian Journal of Pharmacology2014;46:S30. ">Saurabh 2014</a>). </p> <p>When we re‐examined the studies included in the original review, we found that one study did not meet the inclusion criteria (<a href="./references#CD008684-bbs2-0012" title="AdarshK , KaurH , MohanV . Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). BioFactors (Oxford, England)2008;32(1-4):145-9. ">Adarsh 2008</a>). The study did not randomise its participants, and thus, is not an RCT. We deleted the study's findings from the updated review, and added it to the list of excluded studies. </p> <p>See <a href="./references#CD008684-sec-0103" title="">Characteristics of excluded studies</a>. </p> <section id="CD008684-sec-0046"> <h5 class="title">Ongoing studies</h5> <p>We identified two ongoing studies (<a href="./references#CD008684-bbs2-0068" title="NCT02779634. Ubiquinol treatment in patients with heart failure and preserved ejection fraction. clinicaltrials.gov/show/nct02779634 (first posted 20 May 2016). ">NCT02779634</a>; <a href="./references#CD008684-bbs2-0069" title="NCT03133793. CoQ10 and d-ribose in patients with diastolic heart failure. clinicaltrials.gov/show/nct03133793 (first posted 28 April 2017). Pierce JD , Mahoney DE , Hiebert JB , Thimmesch AR , Diaz FJ , SmithC , et al. Study protocol, randomized controlled trial: reducing symptom burden in patients with heart failure with preserved ejection fraction using ubiquinol and/or D-ribose. BMC Cardiovascular Disorders2018;18(1):57. ">Pierce 2018</a>). We contacted authors from both studies; they confirmed that the studies are still ongoing, with no published results yet. Both studies are randomised, blinded, placebo‐controlled trials with parallel design. <a href="./references#CD008684-bbs2-0069" title="NCT03133793. CoQ10 and d-ribose in patients with diastolic heart failure. clinicaltrials.gov/show/nct03133793 (first posted 28 April 2017). Pierce JD , Mahoney DE , Hiebert JB , Thimmesch AR , Diaz FJ , SmithC , et al. Study protocol, randomized controlled trial: reducing symptom burden in patients with heart failure with preserved ejection fraction using ubiquinol and/or D-ribose. BMC Cardiovascular Disorders2018;18(1):57. ">Pierce 2018</a> also investigates D‐ribose supplements and has four arms (placebo only, coenzyme Q10 only, D‐ribose only, coenzyme Q10 plus D‐ribose). <a href="./references#CD008684-bbs2-0068" title="NCT02779634. Ubiquinol treatment in patients with heart failure and preserved ejection fraction. clinicaltrials.gov/show/nct02779634 (first posted 20 May 2016). ">NCT02779634</a> includes participants with heart failure with preserved ejection fraction, and follows them for 16 weeks. <a href="./references#CD008684-bbs2-0069" title="NCT03133793. CoQ10 and d-ribose in patients with diastolic heart failure. clinicaltrials.gov/show/nct03133793 (first posted 28 April 2017). Pierce JD , Mahoney DE , Hiebert JB , Thimmesch AR , Diaz FJ , SmithC , et al. Study protocol, randomized controlled trial: reducing symptom burden in patients with heart failure with preserved ejection fraction using ubiquinol and/or D-ribose. BMC Cardiovascular Disorders2018;18(1):57. ">Pierce 2018</a> also includes participants with heart failure with preserved ejection fraction, and follows them for 12 weeks. </p> <p>See <a href="./references#CD008684-sec-0104" title="">Characteristics of ongoing studies</a>. </p> </section> </section> </section> <section id="CD008684-sec-0047"> <h3 class="title">Risk of bias in included studies</h3> <p>Two review authors independently assessed each of the included studies, and found that there was risk of bias in the included studies (see the 'Risk of bias' tables in the '<a href="./references#CD008684-sec-0102" title="">Characteristics of included studies</a>' tables). We re‐evaluated studies included in the original review for risk of bias. </p> <p>We used the 'Risk of bias' summary and graph figures to illustrate the proportion of studies with each of the judgements (low risk, high risk, unclear risk of bias) for each domain of the tool (<a href="#CD008684-fig-0002">Figure 2</a>; <a href="#CD008684-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD008684-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD008684-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> </div> <div class="figure" id="CD008684-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies" data-id="CD008684-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies </p> </div> </div> </div> <section id="CD008684-sec-0048"> <h4 class="title">Allocation</h4> <p>All included studies stated they were randomised. However, methods used for random sequence generation were not mentioned in seven studies, and thus, we deemed the risk of selection bias (random sequence generation) in these studies to be unclear (<a href="./references#CD008684-bbs2-0001" title="BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(10):A26. BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(5):295-9. ">Berman 2004</a>; <a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>; <a href="./references#CD008684-bbs2-0003" title="KeoghA , FentonS , LeslieC , AboyounC , MacdonaldP , ZhaoYC , et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation2003;12(3):135-41. ">Keogh 2003</a>; <a href="./references#CD008684-bbs2-0005" title="KocharianA , ShabanianR , Rafiei-KhorgamiM , KianiA , Heidari-BateniG , Kocharian Armen, et al. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiology in the Young2009;19(5):501-6. NCT02115581. Coenzyme Q10 supplementation in children with idiopathic dilated cardiomyopathy. clinicaltrials.gov/show/nct02115581 (first posted 16 April 2014). ">Kocharian 2009</a>; <a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>; <a href="./references#CD008684-bbs2-0009" title="MunkholmH , HansenHH , RasmussenK . Coenzyme Q10 treatment in serious heart failure. Biofactors1999;9(2-4):285-9. ">Munkholm 1999</a>; <a href="./references#CD008684-bbs2-0011" title="QingyanZ , OkelloE , YanhongT , BingW , CongxinH . Effect of coenzyme Q10 administration on the incidence of atrial fibrillation in patients with heart failure. Circulation2010;122(2):e209. ZhaoQ , KebbatiAH , ZhangY , TangY , OkelloE , HuangC . Effect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure. Journal of Investigative Medicine2015;63(5):735-9. ">Zhao 2015</a>). We assessed the remaining four studies at low risk of bias for random sequence generation. </p> <p>Nine studies did not mention how they achieved allocation concealment, and therefore, we deemed the risk of selection bias (allocation concealment) to be unclear (<a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>; <a href="./references#CD008684-bbs2-0003" title="KeoghA , FentonS , LeslieC , AboyounC , MacdonaldP , ZhaoYC , et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation2003;12(3):135-41. ">Keogh 2003</a>; <a href="./references#CD008684-bbs2-0004" title="KhattaM , AlexanderBS , KrichtenCM , FisherML , FreudenbergerR , RobinsonSW , et al. The effect of coenzyme Q10 in patients with congestive heart failure. Annals of Internal Medicine2000;132(8):636-40. ">Khatta 2000</a>; <a href="./references#CD008684-bbs2-0005" title="KocharianA , ShabanianR , Rafiei-KhorgamiM , KianiA , Heidari-BateniG , Kocharian Armen, et al. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiology in the Young2009;19(5):501-6. NCT02115581. Coenzyme Q10 supplementation in children with idiopathic dilated cardiomyopathy. clinicaltrials.gov/show/nct02115581 (first posted 16 April 2014). ">Kocharian 2009</a>; <a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>; <a href="./references#CD008684-bbs2-0007" title="MoriscoC , TrimarcoB , CondorelliM . Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clinical Investigator1993;71(8 Suppl):S134-6. ">Morisco 1993</a>; <a href="./references#CD008684-bbs2-0009" title="MunkholmH , HansenHH , RasmussenK . Coenzyme Q10 treatment in serious heart failure. Biofactors1999;9(2-4):285-9. ">Munkholm 1999</a>; <a href="./references#CD008684-bbs2-0010" title="ISRCTN96610559. Coenzyme Q10 supplementation in heart failure with preserved ejection fraction patients. www.isrctn.com/ISRCTN96610559 (date assigned 2 March 2018). SobirinMA , HerryY , SofiaSN , UddinI , RifqiS , TsutsuiH . Effects of coenzyme Q10 supplementation on diastolic function in patients with heart failure with preserved ejection fraction. Drug Discoveries &amp; Therapeutics2019;13(1):38-46. ">Sobirin 2019</a>; <a href="./references#CD008684-bbs2-0011" title="QingyanZ , OkelloE , YanhongT , BingW , CongxinH . Effect of coenzyme Q10 administration on the incidence of atrial fibrillation in patients with heart failure. Circulation2010;122(2):e209. ZhaoQ , KebbatiAH , ZhangY , TangY , OkelloE , HuangC . Effect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure. Journal of Investigative Medicine2015;63(5):735-9. ">Zhao 2015</a>). We assessed the remaining two studies at low risk of bias in this domain. </p> </section> <section id="CD008684-sec-0049"> <h4 class="title">Blinding</h4> <p>Only one study was unblinded, and thus, had a high risk of performance bias (<a href="./references#CD008684-bbs2-0010" title="ISRCTN96610559. Coenzyme Q10 supplementation in heart failure with preserved ejection fraction patients. www.isrctn.com/ISRCTN96610559 (date assigned 2 March 2018). SobirinMA , HerryY , SofiaSN , UddinI , RifqiS , TsutsuiH . Effects of coenzyme Q10 supplementation on diastolic function in patients with heart failure with preserved ejection fraction. Drug Discoveries &amp; Therapeutics2019;13(1):38-46. ">Sobirin 2019</a>). All other included studies were double blinded, and thus, we deemed them at low risk of performance bias. </p> <p><a href="./references#CD008684-bbs2-0010" title="ISRCTN96610559. Coenzyme Q10 supplementation in heart failure with preserved ejection fraction patients. www.isrctn.com/ISRCTN96610559 (date assigned 2 March 2018). SobirinMA , HerryY , SofiaSN , UddinI , RifqiS , TsutsuiH . Effects of coenzyme Q10 supplementation on diastolic function in patients with heart failure with preserved ejection fraction. Drug Discoveries &amp; Therapeutics2019;13(1):38-46. ">Sobirin 2019</a> also had a high risk of detection bias, as it was not blinded. Only three studies mentioned that assessors were blinded, and thus, had a low risk of detection bias (<a href="./references#CD008684-bbs2-0005" title="KocharianA , ShabanianR , Rafiei-KhorgamiM , KianiA , Heidari-BateniG , Kocharian Armen, et al. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiology in the Young2009;19(5):501-6. NCT02115581. Coenzyme Q10 supplementation in children with idiopathic dilated cardiomyopathy. clinicaltrials.gov/show/nct02115581 (first posted 16 April 2014). ">Kocharian 2009</a>; <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>; <a href="./references#CD008684-bbs2-0011" title="QingyanZ , OkelloE , YanhongT , BingW , CongxinH . Effect of coenzyme Q10 administration on the incidence of atrial fibrillation in patients with heart failure. Circulation2010;122(2):e209. ZhaoQ , KebbatiAH , ZhangY , TangY , OkelloE , HuangC . Effect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure. Journal of Investigative Medicine2015;63(5):735-9. ">Zhao 2015</a>). The rest of the studies did not mention blinding of the assessors, and thus, we deemed them at an unclear risk of detection bias (<a href="./references#CD008684-bbs2-0001" title="BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(10):A26. BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(5):295-9. ">Berman 2004</a>; <a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>; <a href="./references#CD008684-bbs2-0003" title="KeoghA , FentonS , LeslieC , AboyounC , MacdonaldP , ZhaoYC , et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation2003;12(3):135-41. ">Keogh 2003</a>; <a href="./references#CD008684-bbs2-0004" title="KhattaM , AlexanderBS , KrichtenCM , FisherML , FreudenbergerR , RobinsonSW , et al. The effect of coenzyme Q10 in patients with congestive heart failure. Annals of Internal Medicine2000;132(8):636-40. ">Khatta 2000</a>; <a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>; <a href="./references#CD008684-bbs2-0007" title="MoriscoC , TrimarcoB , CondorelliM . Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clinical Investigator1993;71(8 Suppl):S134-6. ">Morisco 1993</a>; <a href="./references#CD008684-bbs2-0009" title="MunkholmH , HansenHH , RasmussenK . Coenzyme Q10 treatment in serious heart failure. Biofactors1999;9(2-4):285-9. ">Munkholm 1999</a>). </p> </section> <section id="CD008684-sec-0050"> <h4 class="title">Incomplete outcome data</h4> <p>In eight studies, some of the participants did not finish the study. They were not included in the analysis. We considered these studies to be at high risk of attrition bias (<a href="./references#CD008684-bbs2-0001" title="BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(10):A26. BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(5):295-9. ">Berman 2004</a>; <a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>; <a href="./references#CD008684-bbs2-0003" title="KeoghA , FentonS , LeslieC , AboyounC , MacdonaldP , ZhaoYC , et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation2003;12(3):135-41. ">Keogh 2003</a>; <a href="./references#CD008684-bbs2-0004" title="KhattaM , AlexanderBS , KrichtenCM , FisherML , FreudenbergerR , RobinsonSW , et al. The effect of coenzyme Q10 in patients with congestive heart failure. Annals of Internal Medicine2000;132(8):636-40. ">Khatta 2000</a>; <a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>; <a href="./references#CD008684-bbs2-0007" title="MoriscoC , TrimarcoB , CondorelliM . Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clinical Investigator1993;71(8 Suppl):S134-6. ">Morisco 1993</a>; <a href="./references#CD008684-bbs2-0010" title="ISRCTN96610559. Coenzyme Q10 supplementation in heart failure with preserved ejection fraction patients. www.isrctn.com/ISRCTN96610559 (date assigned 2 March 2018). SobirinMA , HerryY , SofiaSN , UddinI , RifqiS , TsutsuiH . Effects of coenzyme Q10 supplementation on diastolic function in patients with heart failure with preserved ejection fraction. Drug Discoveries &amp; Therapeutics2019;13(1):38-46. ">Sobirin 2019</a>; <a href="./references#CD008684-bbs2-0011" title="QingyanZ , OkelloE , YanhongT , BingW , CongxinH . Effect of coenzyme Q10 administration on the incidence of atrial fibrillation in patients with heart failure. Circulation2010;122(2):e209. ZhaoQ , KebbatiAH , ZhangY , TangY , OkelloE , HuangC . Effect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure. Journal of Investigative Medicine2015;63(5):735-9. ">Zhao 2015</a>). In <a href="./references#CD008684-bbs2-0009" title="MunkholmH , HansenHH , RasmussenK . Coenzyme Q10 treatment in serious heart failure. Biofactors1999;9(2-4):285-9. ">Munkholm 1999</a> and <a href="./references#CD008684-bbs2-0005" title="KocharianA , ShabanianR , Rafiei-KhorgamiM , KianiA , Heidari-BateniG , Kocharian Armen, et al. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiology in the Young2009;19(5):501-6. NCT02115581. Coenzyme Q10 supplementation in children with idiopathic dilated cardiomyopathy. clinicaltrials.gov/show/nct02115581 (first posted 16 April 2014). ">Kocharian 2009</a>, all participants completed the trial, therefore, we considered these studies to be at low risk of attrition bias. <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a> also had participants who did not finish the study, however, their data were included in the intention‐to‐treat analysis for the primary outcomes. Trial authors did not find significant differences between groups in the reasons for withdrawal. Thus, we deemed the risk of attrition bias for this study to be low. </p> </section> <section id="CD008684-sec-0051"> <h4 class="title">Selective reporting</h4> <p>Comparing outcomes reported in the published study was not possible for seven studies, as no published protocols were available (<a href="./references#CD008684-bbs2-0001" title="BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(10):A26. BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(5):295-9. ">Berman 2004</a>; <a href="./references#CD008684-bbs2-0003" title="KeoghA , FentonS , LeslieC , AboyounC , MacdonaldP , ZhaoYC , et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation2003;12(3):135-41. ">Keogh 2003</a>; <a href="./references#CD008684-bbs2-0004" title="KhattaM , AlexanderBS , KrichtenCM , FisherML , FreudenbergerR , RobinsonSW , et al. The effect of coenzyme Q10 in patients with congestive heart failure. Annals of Internal Medicine2000;132(8):636-40. ">Khatta 2000</a>; <a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>; <a href="./references#CD008684-bbs2-0007" title="MoriscoC , TrimarcoB , CondorelliM . Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clinical Investigator1993;71(8 Suppl):S134-6. ">Morisco 1993</a>; <a href="./references#CD008684-bbs2-0009" title="MunkholmH , HansenHH , RasmussenK . Coenzyme Q10 treatment in serious heart failure. Biofactors1999;9(2-4):285-9. ">Munkholm 1999</a>; <a href="./references#CD008684-bbs2-0011" title="QingyanZ , OkelloE , YanhongT , BingW , CongxinH . Effect of coenzyme Q10 administration on the incidence of atrial fibrillation in patients with heart failure. Circulation2010;122(2):e209. ZhaoQ , KebbatiAH , ZhangY , TangY , OkelloE , HuangC . Effect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure. Journal of Investigative Medicine2015;63(5):735-9. ">Zhao 2015</a>). Subsequently, we classified the risk of reporting bias as unclear for these studies. We assessed only one study at a high risk of reporting bias, as some of the outcomes listed in the protocol were not reported in the manuscript (<a href="./references#CD008684-bbs2-0010" title="ISRCTN96610559. Coenzyme Q10 supplementation in heart failure with preserved ejection fraction patients. www.isrctn.com/ISRCTN96610559 (date assigned 2 March 2018). SobirinMA , HerryY , SofiaSN , UddinI , RifqiS , TsutsuiH . Effects of coenzyme Q10 supplementation on diastolic function in patients with heart failure with preserved ejection fraction. Drug Discoveries &amp; Therapeutics2019;13(1):38-46. ">Sobirin 2019</a>). We assessed the remaining three studies at low risk of reporting bias. </p> </section> <section id="CD008684-sec-0052"> <h4 class="title">Other potential sources of bias</h4> <p>None reported.</p> </section> </section> <section id="CD008684-sec-0053"> <h3 class="title" id="CD008684-sec-0053">Effects of interventions</h3> <p>See: <a href="./full#CD008684-tbl-0001"><b>Summary of findings 1</b> Coenzyme Q10 compared to placebo or conventional therapy for heart failure</a> </p> <p>We found no studies that compared coenzyme Q10 to other active agent for heart failure, or compared a high dose to a low dose of coenzyme Q10. All eleven included studies compared coenzyme Q10 to either placebo or conventional therapy. We combined the results from all of the studies into one comparison, coenzyme Q10 versus control, where control referred to placebo plus conventional therapy, or conventional therapy alone. </p> <section id="CD008684-sec-0054"> <h4 class="title">Primary outcomes</h4> <p>Two studies reported on some or all of the following primary outcomes: total mortality, major cardiovascular events, myocardial infarction, stroke, revascularisation procedures, and hospitalisation (<a href="./references#CD008684-bbs2-0007" title="MoriscoC , TrimarcoB , CondorelliM . Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clinical Investigator1993;71(8 Suppl):S134-6. ">Morisco 1993</a>; <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>). Seven studies reported on the New York Heart Association (NYHA) functional class (<a href="./references#CD008684-bbs2-0001" title="BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(10):A26. BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(5):295-9. ">Berman 2004</a>; <a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>; <a href="./references#CD008684-bbs2-0003" title="KeoghA , FentonS , LeslieC , AboyounC , MacdonaldP , ZhaoYC , et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation2003;12(3):135-41. ">Keogh 2003</a>; <a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>; <a href="./references#CD008684-bbs2-0007" title="MoriscoC , TrimarcoB , CondorelliM . Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clinical Investigator1993;71(8 Suppl):S134-6. ">Morisco 1993</a>; <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>; <a href="./references#CD008684-bbs2-0009" title="MunkholmH , HansenHH , RasmussenK . Coenzyme Q10 treatment in serious heart failure. Biofactors1999;9(2-4):285-9. ">Munkholm 1999</a>). </p> <p>In the primary report, <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a> reported these outcomes as components of adverse events, and compared them between the two study groups as adverse events rather than as separate outcomes. We extracted these data and directly compared between coenzyme Q10 and control. </p> <section id="CD008684-sec-0055"> <h5 class="title">All‐cause mortality</h5> <p>One study reported data on mortality (<a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>). Coenzyme Q10 (CoQ10) was probably reduces all‐cause mortality (10% in the intervention group versus 18% in the control group; risk ratio (RR) 0.58, 95% confidence interval (CI) 0.35 to 0.95; one study, 420 participants; <a href="./references#CD008684-fig-0004" title="">Analysis 1.1</a>; moderate‐quality evidence) at 106 weeks, and was also superior to control for all‐cause mortality survival (hazard ratio (HR) 0.51; 95% CI 0.30 to 0.89; P = 0.018, as reported by <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>). The number needed to treat for an additional beneficial outcome (NNTB) was 13.3. We downgraded the evidence by one level due to indirectness (<a href="./full#CD008684-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD008684-sec-0056"> <h5 class="title">Cardiovascular mortality</h5> <p>One study reported data on cardiovascular mortality (<a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>). Coenzyme Q10 probably reduces the risk of cardiovascular mortality (9% in CoQ10 group versus 16% in control group; P = 0.039) at 106 weeks, with a NNTB of 15. We downgraded the evidence by one level, to moderate quality, due to indirectness. </p> <p><a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a> also reported on major cardiovascular events (defined as unplanned hospital stay resulting from worsening heart failure, cardiovascular death, mechanical assist implantation, or urgent cardiac transplantation). There were fewer cardiovascular events in the coenzyme Q10 group compared to the control group (15% in CoQ10 group versus 26% in control group; P = 0.005) at 106 weeks. CoQ10 was also superior to control in time‐to‐event analysis for cardiovascular events (HR 0.50; 95% CI 0.32 to 0.80; P = 0.003, as reported by <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>). </p> </section> <section id="CD008684-sec-0057"> <h5 class="title">Fatal and non‐fatal myocardial infarction</h5> <p>One study reported data on myocardial infarction (<a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>). The results were inconclusive for the risk of myocardial infarction between the CoQ10 and control groups (RR 1.62, 95% CI 0.27 to 9.59; one study, 420 participants; low‐quality evidence; <a href="./references#CD008684-fig-0005" title="">Analysis 1.2</a>). We downgraded the quality of the evidence two levels for indirectness and imprecision (<a href="./full#CD008684-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD008684-sec-0058"> <h5 class="title">Fatal and non‐fatal stroke</h5> <p>One study reported data on strokes (<a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>). There was little or no difference in the risk of stroke between the CoQ10 and control groups (RR 0.18, 95% CI 0.02 to 1.48; one study, 420 participants; low‐quality evidence; <a href="./references#CD008684-fig-0006" title="">Analysis 1.3</a>). Thus, the results were inconclusive between groups for the risk of stroke. We downgraded the quality of the evidence two levels for indirectness and imprecision (<a href="./full#CD008684-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD008684-sec-0059"> <h5 class="title">Revascularisation procedures (percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG)) </h5> <p>One study reported data on revascularisation procedures (<a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>). The results were inconclusive between groups for the risk of revascularization procedures compared to control (RR 0.86, 95% CI 0.24 to 3.17; one study, 420 participants; <a href="./references#CD008684-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD008684-sec-0060"> <h5 class="title">Hospitalisation due to heart failure</h5> <p>Two studies reported data on hospitalisation due to heart failure (<a href="./references#CD008684-bbs2-0007" title="MoriscoC , TrimarcoB , CondorelliM . Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clinical Investigator1993;71(8 Suppl):S134-6. ">Morisco 1993</a>; <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>). Coenzyme Q10 probably reduces hospitalisations due to heart failure when compared to control (RR 0.62, 95% CI 0.49 to 0.78; two studies, 1061 participants; I² = 0%; moderate‐quality evidence; <a href="./references#CD008684-fig-0008" title="">Analysis 1.5</a>). The NNTB was 9.7. </p> <p>It is worth mentioning that those two studies were published more than 20 years apart, and reflect significant changes in medical care and hospitalisation criteria for people with heart failure over this time period. In <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>, hospital stays within 30 days of randomisation were not counted. We downgraded the quality of the evidence due to high risk of bias (<a href="./full#CD008684-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD008684-sec-0061"> <h5 class="title">All‐cause hospitalisation</h5> <p>None of the included studies reported on all‐cause hospitalisation.</p> </section> <section id="CD008684-sec-0062"> <h5 class="title">New York Heart Association (NYHA) classification of clinical status</h5> <p>Seven trials reported on NYHA functional classification (<a href="./references#CD008684-bbs2-0001" title="BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(10):A26. BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(5):295-9. ">Berman 2004</a>; <a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>; <a href="./references#CD008684-bbs2-0003" title="KeoghA , FentonS , LeslieC , AboyounC , MacdonaldP , ZhaoYC , et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation2003;12(3):135-41. ">Keogh 2003</a>; <a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>; <a href="./references#CD008684-bbs2-0007" title="MoriscoC , TrimarcoB , CondorelliM . Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clinical Investigator1993;71(8 Suppl):S134-6. ">Morisco 1993</a>; <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>; <a href="./references#CD008684-bbs2-0009" title="MunkholmH , HansenHH , RasmussenK . Coenzyme Q10 treatment in serious heart failure. Biofactors1999;9(2-4):285-9. ">Munkholm 1999</a>). They used different methods to report the change in NYHA clinical status, and therefore, we were unable to pool the results. </p> <p><a href="./references#CD008684-bbs2-0001" title="BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(10):A26. BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(5):295-9. ">Berman 2004</a> reported that the median NYHA class in the coenzyme Q10 group decreased from 3.1 to 2.4, whereas no change was reported in the control group (from median 3.68 to 3.6). </p> <p><a href="./references#CD008684-bbs2-0003" title="KeoghA , FentonS , LeslieC , AboyounC , MacdonaldP , ZhaoYC , et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation2003;12(3):135-41. ">Keogh 2003</a> reported that the NYHA class in the coenzyme Q10 group showed a small (0.5) but significant (P = 0.0001) improvement, whereas the control group showed no significant change. In the coenzyme Q10 group, the NYHA class improved from 2.9 (± 0.06) to 2.4 (± 0.12); P = 0.001. The difference in improvement between the coenzyme Q10 group and the control group in mean NYHA class was 0.5, which was statistically significant for the t‐test (P = 0.012) and for the Wilcoxon test (P = 0.02). </p> <p><a href="./references#CD008684-bbs2-0007" title="MoriscoC , TrimarcoB , CondorelliM . Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clinical Investigator1993;71(8 Suppl):S134-6. ">Morisco 1993</a> reported that there was a progressive reduction in the NYHA class in the coenzyme Q10 group, indicating an improvement in functional status that was statistically significant after three, six, and at 12 months. No significant change in functional class was observed in the control group. </p> <p><a href="./references#CD008684-bbs2-0009" title="MunkholmH , HansenHH , RasmussenK . Coenzyme Q10 treatment in serious heart failure. Biofactors1999;9(2-4):285-9. ">Munkholm 1999</a> reported that the participants in the coenzyme Q10 group tended to improve with respect to their functional class (from 3A to 2B), whereas no improvement was reported in the control group (2B). However, the improvement in the treatment group was not statistically significant. </p> <p><a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>, a cross‐over trial, reported data on NYHA functional class, however, they did not provide data separately for the first phase. </p> <p><a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a> reported non‐significant improvement in NYHA functional class in both the coenzyme Q10 and control groups at 16 weeks. However, at 106 weeks, a significantly larger proportion of participants in the coenzyme Q10 group showed NYHA functional class improvement compared to the control group (58% versus 45%; P = 0.028). </p> <p><a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a> reported a greater change of NYHA functional class in the coenzyme Q10 group (NYHA class change ‐0.16) compared to the control group (‐0.08; P = 0.033). </p> </section> </section> <section id="CD008684-sec-0063"> <h4 class="title">Secondary outcomes</h4> <p>None of the included trials measured quality of life, measured by a recognised scale, exercise variables (exercise haemodynamics), or cost‐effectiveness. </p> <section id="CD008684-sec-0064"> <h5 class="title">Left ventricular ejection fraction (LVEF)</h5> <p>Eight trials reported on left ventricular ejection fraction (<a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>; <a href="./references#CD008684-bbs2-0004" title="KhattaM , AlexanderBS , KrichtenCM , FisherML , FreudenbergerR , RobinsonSW , et al. The effect of coenzyme Q10 in patients with congestive heart failure. Annals of Internal Medicine2000;132(8):636-40. ">Khatta 2000</a>; <a href="./references#CD008684-bbs2-0005" title="KocharianA , ShabanianR , Rafiei-KhorgamiM , KianiA , Heidari-BateniG , Kocharian Armen, et al. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiology in the Young2009;19(5):501-6. NCT02115581. Coenzyme Q10 supplementation in children with idiopathic dilated cardiomyopathy. clinicaltrials.gov/show/nct02115581 (first posted 16 April 2014). ">Kocharian 2009</a>; <a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>; <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>; <a href="./references#CD008684-bbs2-0009" title="MunkholmH , HansenHH , RasmussenK . Coenzyme Q10 treatment in serious heart failure. Biofactors1999;9(2-4):285-9. ">Munkholm 1999</a>; <a href="./references#CD008684-bbs2-0010" title="ISRCTN96610559. Coenzyme Q10 supplementation in heart failure with preserved ejection fraction patients. www.isrctn.com/ISRCTN96610559 (date assigned 2 March 2018). SobirinMA , HerryY , SofiaSN , UddinI , RifqiS , TsutsuiH . Effects of coenzyme Q10 supplementation on diastolic function in patients with heart failure with preserved ejection fraction. Drug Discoveries &amp; Therapeutics2019;13(1):38-46. ">Sobirin 2019</a>; <a href="./references#CD008684-bbs2-0011" title="QingyanZ , OkelloE , YanhongT , BingW , CongxinH . Effect of coenzyme Q10 administration on the incidence of atrial fibrillation in patients with heart failure. Circulation2010;122(2):e209. ZhaoQ , KebbatiAH , ZhangY , TangY , OkelloE , HuangC . Effect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure. Journal of Investigative Medicine2015;63(5):735-9. ">Zhao 2015</a>). Data from <a href="./references#CD008684-bbs2-0004" title="KhattaM , AlexanderBS , KrichtenCM , FisherML , FreudenbergerR , RobinsonSW , et al. The effect of coenzyme Q10 in patients with congestive heart failure. Annals of Internal Medicine2000;132(8):636-40. ">Khatta 2000</a> were not useable as they did not report standard deviations. Five studies used echocardiography to assess ejection fraction (<a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>; <a href="./references#CD008684-bbs2-0005" title="KocharianA , ShabanianR , Rafiei-KhorgamiM , KianiA , Heidari-BateniG , Kocharian Armen, et al. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiology in the Young2009;19(5):501-6. NCT02115581. Coenzyme Q10 supplementation in children with idiopathic dilated cardiomyopathy. clinicaltrials.gov/show/nct02115581 (first posted 16 April 2014). ">Kocharian 2009</a>; <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>; <a href="./references#CD008684-bbs2-0010" title="ISRCTN96610559. Coenzyme Q10 supplementation in heart failure with preserved ejection fraction patients. www.isrctn.com/ISRCTN96610559 (date assigned 2 March 2018). SobirinMA , HerryY , SofiaSN , UddinI , RifqiS , TsutsuiH . Effects of coenzyme Q10 supplementation on diastolic function in patients with heart failure with preserved ejection fraction. Drug Discoveries &amp; Therapeutics2019;13(1):38-46. ">Sobirin 2019</a>; <a href="./references#CD008684-bbs2-0011" title="QingyanZ , OkelloE , YanhongT , BingW , CongxinH . Effect of coenzyme Q10 administration on the incidence of atrial fibrillation in patients with heart failure. Circulation2010;122(2):e209. ZhaoQ , KebbatiAH , ZhangY , TangY , OkelloE , HuangC . Effect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure. Journal of Investigative Medicine2015;63(5):735-9. ">Zhao 2015</a>). One study used radionuclide ventriculography (<a href="./references#CD008684-bbs2-0009" title="MunkholmH , HansenHH , RasmussenK . Coenzyme Q10 treatment in serious heart failure. Biofactors1999;9(2-4):285-9. ">Munkholm 1999</a>), and one study used either echocardiography, contrast, or radionuclide ventriculography (<a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>). Two studies reported LVEF at two separate time points (16 and 106 weeks for <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>; 6 and 12 months for <a href="./references#CD008684-bbs2-0011" title="QingyanZ , OkelloE , YanhongT , BingW , CongxinH . Effect of coenzyme Q10 administration on the incidence of atrial fibrillation in patients with heart failure. Circulation2010;122(2):e209. ZhaoQ , KebbatiAH , ZhangY , TangY , OkelloE , HuangC . Effect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure. Journal of Investigative Medicine2015;63(5):735-9. ">Zhao 2015</a>), however, we only used the data from the longest follow‐up. </p> <p>Coenzyme Q10 was associated with a small change in LVEF (mean difference (MD) 1.77, 95% CI 0.09 to 3.44; seven studies, 650 participants; I² = 38%; very low‐quality evidence; <a href="./references#CD008684-fig-0009" title="">Analysis 1.6</a>). We assessed the quality of evidence for this outcome as very low, because of the substantial risk of bias in most of the studies, and the lack of precision, due to the wide confidence intervals (<a href="./full#CD008684-tbl-0001">summary of findings Table 1</a>). Thus, it is uncertain whether Coenzyme Q10 improves LVEF or not. </p> </section> <section id="CD008684-sec-0065"> <h5 class="title">Symptom improvement</h5> <p>Overall, six trials reported on symptom improvement (<a href="./references#CD008684-bbs2-0001" title="BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(10):A26. BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(5):295-9. ">Berman 2004</a>; <a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>; <a href="./references#CD008684-bbs2-0003" title="KeoghA , FentonS , LeslieC , AboyounC , MacdonaldP , ZhaoYC , et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation2003;12(3):135-41. ">Keogh 2003</a>; <a href="./references#CD008684-bbs2-0004" title="KhattaM , AlexanderBS , KrichtenCM , FisherML , FreudenbergerR , RobinsonSW , et al. The effect of coenzyme Q10 in patients with congestive heart failure. Annals of Internal Medicine2000;132(8):636-40. ">Khatta 2000</a>; <a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>; <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>). </p> <section id="CD008684-sec-0066"> <h6 class="title">Treadmill exercise test duration (seconds)</h6> <p>Three studies reported on exercise capacity, using the duration of treadmill exercise (<a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>; <a href="./references#CD008684-bbs2-0003" title="KeoghA , FentonS , LeslieC , AboyounC , MacdonaldP , ZhaoYC , et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation2003;12(3):135-41. ">Keogh 2003</a>; <a href="./references#CD008684-bbs2-0004" title="KhattaM , AlexanderBS , KrichtenCM , FisherML , FreudenbergerR , RobinsonSW , et al. The effect of coenzyme Q10 in patients with congestive heart failure. Annals of Internal Medicine2000;132(8):636-40. ">Khatta 2000</a>). Reviewing data from the original version of the review, we found that we had mistakenly switched the numbers for coenzyme Q10 and control groups in the analysis; and input inaccurate numbers of participants in each group for <a href="./references#CD008684-bbs2-0003" title="KeoghA , FentonS , LeslieC , AboyounC , MacdonaldP , ZhaoYC , et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation2003;12(3):135-41. ">Keogh 2003</a>; and inaccurately converted minutes to seconds for the coenzyme Q10 group in <a href="./references#CD008684-bbs2-0004" title="KhattaM , AlexanderBS , KrichtenCM , FisherML , FreudenbergerR , RobinsonSW , et al. The effect of coenzyme Q10 in patients with congestive heart failure. Annals of Internal Medicine2000;132(8):636-40. ">Khatta 2000</a>, although the accurate numbers were not significantly different. We subsequently corrected those numbers for this version. </p> <p>The results were inconclusive for exercise duration between the coenzyme Q10 and control groups (MD 48.23, 95% CI ‐24.75 to 121.20; three studies, 91 participants; I² = 41%; <a href="./references#CD008684-fig-0010" title="">Analysis 1.7</a>). The sample size for this outcome is very small; it includes studies with high risk of bias; and the effect is imprecise (very wide confidence interval that includes possible harm, no effect, or possible benefit). Thus, the quality of evidence is very low, and it is uncertain whether coenzyme Q10 affects this outcome (<a href="./full#CD008684-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD008684-sec-0067"> <h6 class="title">Treadmill exercise metabolic equivalents (MET)</h6> <p>One study reported data on exercise capacity using treadmill exercise test metabolic equivalents (METs) (<a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>). Because this cross‐over study did not report analysis for the first phase, we conducted the analysis using data provided by the authors. At three months, the results were inconclusive for METs on the treadmill exercise test between the coenzyme Q10 and control groups (MD ‐2.51, 95% CI ‐6.35 to 1.33; one study, nine participants; <a href="./references#CD008684-fig-0011" title="">Analysis 1.8</a>). This effect is imprecise and potentially biased. </p> </section> <section id="CD008684-sec-0068"> <h6 class="title">6‐minute walk distance (metres)</h6> <p>Four studies reported on exercise capacity using 6‐minute walk test distance (<a href="./references#CD008684-bbs2-0001" title="BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(10):A26. BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(5):295-9. ">Berman 2004</a>; <a href="./references#CD008684-bbs2-0003" title="KeoghA , FentonS , LeslieC , AboyounC , MacdonaldP , ZhaoYC , et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation2003;12(3):135-41. ">Keogh 2003</a>; <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>, <a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>). </p> <p><a href="./references#CD008684-bbs2-0001" title="BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(10):A26. BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(5):295-9. ">Berman 2004</a> noted improvement from baseline in the coenzyme Q10 group (269.5 to 382.2 metres; P &lt; 0.0001), and deterioration in the control group (254 to 177 metres). </p> <p><a href="./references#CD008684-bbs2-0003" title="KeoghA , FentonS , LeslieC , AboyounC , MacdonaldP , ZhaoYC , et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation2003;12(3):135-41. ">Keogh 2003</a> found no difference in response between coenzyme Q10 and placebo (an increase of 21 meters in the coenzyme Q10 group, and a decrease of 16 meters in the control group; P = 0.29). </p> <p><a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a> reported improvement in the 6‐minute walk test in both the coenzyme Q10 and control groups at 16 weeks; the difference between groups was not significantly different. </p> <p><a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a> reported improvement in both the coenzyme Q10 (288 to 320 metres; P = 0.001) and control groups (311 to 324 metres; P = 0.103); as well as in between the two groups (P = 0.03). </p> <p>We could not pool data for the 6‐minute walk distance as <a href="./references#CD008684-bbs2-0001" title="BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(10):A26. BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(5):295-9. ">Berman 2004</a> and <a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a> did not report standard deviation (SD), and <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a> reported only the differences from baseline. </p> </section> <section id="CD008684-sec-0069"> <h6 class="title">Visual analogue scale (VAS)</h6> <p>One study evaluated symptom improvement with a visual analogue scale (VAS) at 16 weeks (<a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>). It found improvement in both groups; but no difference between groups was found. </p> </section> <section id="CD008684-sec-0070"> <h6 class="title">The Minnesota living with heart failure questionnaire</h6> <p>One study reported on symptom improvement by measuring changes in the Minnesota living with heart failure questionnaire at 24 weeks (<a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>). They found a decrease of 9.1 points in the scores for both the coenzyme Q10 and control groups. </p> </section> <section id="CD008684-sec-0071"> <h6 class="title">The Kansas city cardiomyopathy questionnaire (KCCQ)</h6> <p>One study reported on symptom improvement by measuring changes in the Kansas city cardiomyopathy questionnaire score at 24 weeks (<a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>). There was a larger increase in score for the coenzyme Q10 group (+9.9) compared to the control (+1.4; P = 0.034). </p> </section> <section id="CD008684-sec-0072"> <h6 class="title">Other exercise variables – peak oxygen consumption</h6> <p>One study reported data for peak oxygen consumption (<a href="./references#CD008684-bbs2-0004" title="KhattaM , AlexanderBS , KrichtenCM , FisherML , FreudenbergerR , RobinsonSW , et al. The effect of coenzyme Q10 in patients with congestive heart failure. Annals of Internal Medicine2000;132(8):636-40. ">Khatta 2000</a>). Data showed an increase in the coenzyme Q10 group and a decrease in the control group; but no significant difference between the two groups. </p> </section> <section id="CD008684-sec-0073"> <h6 class="title">Brain natriuretic peptide (BNP) and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP)</h6> <p>Two studies reported on BNP (<a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>; <a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>). BNP blood levels were less in the coenzyme Q10 group compared to control (MD ‐91.97, 95% CI ‐103.11 to ‐80.83; two studies, 162 participants; I² = 0%; <a href="./references#CD008684-fig-0012" title="">Analysis 1.9</a>). </p> <p>One study reported on NT‐proBNP (<a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>). It found no difference in change from baseline for NT‐proBNP blood levels between the two groups at 16 and 106 weeks. </p> </section> <section id="CD008684-sec-0074"> <h6 class="title">Serum levels of coenzyme Q10</h6> <p>Seven studies reported data on coenzyme Q10 serum levels (<a href="./references#CD008684-bbs2-0001" title="BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(10):A26. BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(5):295-9. ">Berman 2004</a>; <a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>; <a href="./references#CD008684-bbs2-0003" title="KeoghA , FentonS , LeslieC , AboyounC , MacdonaldP , ZhaoYC , et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation2003;12(3):135-41. ">Keogh 2003</a>; <a href="./references#CD008684-bbs2-0004" title="KhattaM , AlexanderBS , KrichtenCM , FisherML , FreudenbergerR , RobinsonSW , et al. The effect of coenzyme Q10 in patients with congestive heart failure. Annals of Internal Medicine2000;132(8):636-40. ">Khatta 2000</a>; <a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>; <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>; <a href="./references#CD008684-bbs2-0009" title="MunkholmH , HansenHH , RasmussenK . Coenzyme Q10 treatment in serious heart failure. Biofactors1999;9(2-4):285-9. ">Munkholm 1999</a>). We were unable to use data from <a href="./references#CD008684-bbs2-0001" title="BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(10):A26. BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(5):295-9. ">Berman 2004</a> as they did not report standard deviations. One study reported coenzyme Q10 serum levels at two separate time points (16 and 106 weeks; (<a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>)). </p> <p>Coenzyme Q10 serum levels were higher for those taking the supplement compared to control (MD 1.25, 95% CI 1.09 to 1.42; six studies, 489 participants; I² = 91%; <a href="./references#CD008684-fig-0013" title="">Analysis 1.10</a>). The high level of heterogeneity was likely due to the differences in coenzyme Q10 levels, caused by different daily coenzyme Q10 regimens administered among the studies. The daily dose of coenzyme Q10 was higher in three studies (400 mg in <a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>; 300 mg in <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>; 225 mg in <a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>), compared to the other studies (150 mg in <a href="./references#CD008684-bbs2-0003" title="KeoghA , FentonS , LeslieC , AboyounC , MacdonaldP , ZhaoYC , et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation2003;12(3):135-41. ">Keogh 2003</a>; 200 mg in <a href="./references#CD008684-bbs2-0004" title="KhattaM , AlexanderBS , KrichtenCM , FisherML , FreudenbergerR , RobinsonSW , et al. The effect of coenzyme Q10 in patients with congestive heart failure. Annals of Internal Medicine2000;132(8):636-40. ">Khatta 2000</a>; 200 mg in <a href="./references#CD008684-bbs2-0009" title="MunkholmH , HansenHH , RasmussenK . Coenzyme Q10 treatment in serious heart failure. Biofactors1999;9(2-4):285-9. ">Munkholm 1999</a>). Therefore, we conducted a subgroup analysis to compare studies without a maximum coenzyme Q10 dose against those with a maximum dose of 200 mg daily. </p> <section id="CD008684-sec-0075"> <p><b>Subgroup analysis</b></p> <p>Analysis for studies with doses ≤ 200 mg daily continued to show a higher coenzyme Q10 level in those who received coenzyme Q10 compared to the control group (MD 1.46, 95% CI 1.19 to 1.72; three studies, 112 participants; I² = 29%; <a href="./references#CD008684-fig-0013" title="">Analysis 1.10</a>). </p> <p>Test for subgroup differences indicated evidence for a difference between effect based on maximum dosage (P = 0.04). Heterogeneity, however, remained high in the analysis for studies with dose &gt; 200mg daily, which is unexplained (I² = 93%; <a href="./references#CD008684-fig-0013" title="">Analysis 1.10</a>). The effect is inconsistent given the unexplained heterogeneity and potentially biased given the high risk of bias in the included studies. </p> </section> </section> <section id="CD008684-sec-0076"> <h6 class="title">Adverse events</h6> <p>Two studies reported on adverse events (<a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>; <a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>). The results were inconclusive between groups (RR 0.70, 95% CI 0.45 to 1.10; two studies, 568 participants; I² = 0%; low‐quality evidence; <a href="./references#CD008684-fig-0014" title="">Analysis 1.11</a>). We downgraded the quality of the evidence two levels, due to indirectness and imprecision, shown by the wide confidence interval (<a href="./full#CD008684-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD008684-sec-0077"> <h6 class="title">Other cardiovascular outcomes</h6> <p><a href="./references#CD008684-bbs2-0007" title="MoriscoC , TrimarcoB , CondorelliM . Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clinical Investigator1993;71(8 Suppl):S134-6. ">Morisco 1993</a> reported that the percentage incidence of acute pulmonary oedema was significantly smaller in the coenzyme Q10 group than in the control group (P &lt; 0.001). They also found the incidence of cardiac asthma was lower in participants treated with coenzyme Q10 than those in the control group (P &lt; 0.001). The incidence of arrhythmias was higher in the control group than in the coenzyme Q10 group (P &lt; 0.001). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008684-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008684-sec-0078"></div> <section id="CD008684-sec-0079"> <h3 class="title" id="CD008684-sec-0079">Summary of main results</h3> <p>We included 11 studies comparing coenzyme Q10 to placebo. All had small sample size and all but one study (<a href="./references#CD008684-bbs2-0005" title="KocharianA , ShabanianR , Rafiei-KhorgamiM , KianiA , Heidari-BateniG , Kocharian Armen, et al. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiology in the Young2009;19(5):501-6. NCT02115581. Coenzyme Q10 supplementation in children with idiopathic dilated cardiomyopathy. clinicaltrials.gov/show/nct02115581 (first posted 16 April 2014). ">Kocharian 2009</a>) were performed on adults. Only one of the included studies had a crossover design (<a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>). Follow up periods varied among the included studies: up to 6 months for 8 studies (<a href="./references#CD008684-bbs2-0001" title="BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(10):A26. BermanM , ErmanA , Ben-GalT , DvirD , GeorghiouGP , StamlerA , et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology2004;27(5):295-9. ">Berman 2004</a>; <a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>; <a href="./references#CD008684-bbs2-0003" title="KeoghA , FentonS , LeslieC , AboyounC , MacdonaldP , ZhaoYC , et al. Randomised double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung and Circulation2003;12(3):135-41. ">Keogh 2003</a>; <a href="./references#CD008684-bbs2-0004" title="KhattaM , AlexanderBS , KrichtenCM , FisherML , FreudenbergerR , RobinsonSW , et al. The effect of coenzyme Q10 in patients with congestive heart failure. Annals of Internal Medicine2000;132(8):636-40. ">Khatta 2000</a>; <a href="./references#CD008684-bbs2-0005" title="KocharianA , ShabanianR , Rafiei-KhorgamiM , KianiA , Heidari-BateniG , Kocharian Armen, et al. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiology in the Young2009;19(5):501-6. NCT02115581. Coenzyme Q10 supplementation in children with idiopathic dilated cardiomyopathy. clinicaltrials.gov/show/nct02115581 (first posted 16 April 2014). ">Kocharian 2009</a>; <a href="./references#CD008684-bbs2-0006" title="MareevVY , MininaYV , MareevYV . Coenzyme Q-10 in treatment of patients with heart failure: results Russian multicenter double blind placebo controlled study. European Journal of Heart Failure2017;19(Suppl 1):56. ">Mareev 2017</a>; <a href="./references#CD008684-bbs2-0009" title="MunkholmH , HansenHH , RasmussenK . Coenzyme Q10 treatment in serious heart failure. Biofactors1999;9(2-4):285-9. ">Munkholm 1999</a>; <a href="./references#CD008684-bbs2-0010" title="ISRCTN96610559. Coenzyme Q10 supplementation in heart failure with preserved ejection fraction patients. www.isrctn.com/ISRCTN96610559 (date assigned 2 March 2018). SobirinMA , HerryY , SofiaSN , UddinI , RifqiS , TsutsuiH . Effects of coenzyme Q10 supplementation on diastolic function in patients with heart failure with preserved ejection fraction. Drug Discoveries &amp; Therapeutics2019;13(1):38-46. ">Sobirin 2019</a>), up to 12 months for two studies (<a href="./references#CD008684-bbs2-0007" title="MoriscoC , TrimarcoB , CondorelliM . Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clinical Investigator1993;71(8 Suppl):S134-6. ">Morisco 1993</a>; <a href="./references#CD008684-bbs2-0011" title="QingyanZ , OkelloE , YanhongT , BingW , CongxinH . Effect of coenzyme Q10 administration on the incidence of atrial fibrillation in patients with heart failure. Circulation2010;122(2):e209. ZhaoQ , KebbatiAH , ZhangY , TangY , OkelloE , HuangC . Effect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure. Journal of Investigative Medicine2015;63(5):735-9. ">Zhao 2015</a>), and 26 months for only one study (<a href="./references#CD008684-bbs2-0008" title="EUCTR 2005-002960-27-HU. Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on symptoms, biomarker status (BNP) and long-term outcome (hospitalisation/mortality) (Q-Symbio). www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2005-002960-27-HU (first entered 20 January 2006). ISRCTN94506234. Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide (BNP)), and long-term outcome (hospitalisations/mortality). www.isrctn.com/ISRCTN94506234 (date assigned 23 April 2007). MortensenAL , RosenfeldtF , FilipiakKJ . Effect of coenzyme Q10 in Europeans with chronic heart failure: a sub-group analysis of the Q-SYMBIO randomized double-blind trial. Cardiology Journal2019;26(2):147-56. MortensenSA , DollinerP , FilipiakKJ , AlehagenU , PellaD , SteurerG , et al. Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO study?European Heart Journal2015;36:659-60. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. Long-term results with coenzyme Q10 as adjunctive therapy in chronic heart failure. Heart2013;99:A55-6. MortensenSA , KumarA , DollinerP , FilipiakKJ , PellaD , AlehagenU , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure2013;12:S21. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. Coenzyme Q10 therapy blocks the vicious metabolic cycle in chronic heart failure. Journal of Cardiac Failure2013;1:S25. MortensenSA , RosenfeldtF , KumarA , DollinerP , FilipiakKJ , PellaD , et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure2014;2(6):641-9. ">Mortensen 2014</a>). </p> <p>Many of the outcomes were reported by only one of the included studies so no meta‐analyses were done. For those outcomes reported by multiple studies, we were not able to combine some of them (NYHA functional class and symptoms improvement in terms of 6‐minutes walk test) due to the variability in reporting. </p> <section id="CD008684-sec-0080"> <h4 class="title">Primary outcomes</h4> <p>Moderate‐level evidence showed that coenzyme Q10 probably reduces the risk of all cause and cardiovascular mortality at 106 weeks (evidence from one study) and hospitalisations for heart failure (evidence from two studies). </p> <p>Results from individual studies showed lower incidence of acute pulmonary oedema, cardiac asthma and arrhythmia, and fewer cardiovascular events (defined as unplanned hospital stay resulting from worsening HF, cardiovascular death, mechanical assist implantation, or urgent cardiac transplantation) with coenzyme Q10. However results were inconclusive for risk of myocardial infarction, stroke or revascularisation procedures. </p> <p>Although seven studies reported on NYHA classification, we were unable to pool the results since they used different methods to report the change. Nevertheless, individual studies showed evidence of improvement in NYHA classification with coenzyme Q10. </p> </section> <section id="CD008684-sec-0081"> <h4 class="title">Secondary outcomes</h4> <p>Although many studies reported on LVEF, low‐quality evidence leaves us uncertain about the effect of coenzyme Q10 on left ventricular ejection fraction (LVEF). The analysis showed improvement in the LVEF with coenzyme Q10, however, the effect size was small and likely not clinically significant (from 0.09% to 3.44% higher). </p> <p>Overall, coenzyme Q10 was not associated with better outcomes for peak oxygen consumption, the duration of treadmill exercise, treadmill exercise metabolic equivalents, or heart failure symptoms measured on a visual analogue scale and the Minnesota living with heart failure questionnaire. It, however, improves the distance of the 6‐minutes walk test and heart failure symptoms measured by the Kansas city cardiomyopathy questionnaire. </p> <p>Coenzyme Q10 supplements results in higher serum levels of coenzyme Q10, even with a maximum daily dose of 200 mg daily. These findings, however, have significant inconsistency due to unexplained heterogeneity. Furthermore, coenzyme Q10 lowers BNP blood levels; but not lower NT‐proBNP. The results for adverse events associated with coenzyme Q10 were inconclusive. </p> </section> </section> <section id="CD008684-sec-0082"> <h3 class="title" id="CD008684-sec-0082">Overall completeness and applicability of evidence</h3> <p>We were unable to pool the data for most of the outcomes, since they were reported in different ways in different studies, reported in only one study, or not reported in any study. For instance, important outcomes in heart failure (e.g. mortality, cardiovascular events, hospitalisation, adverse events) were rarely investigated. For other important outcomes, like symptom improvement and New York Heart Association classification status, assessment methods and numbers reported varied among studies, limiting our ability to conduct meta‐analyses. The dose of coenzyme Q10 also varied among the studies. </p> <p>Small sample sizes, short follow up periods and lack of usable data inhibited our ability to pool the data and draw robust conclusions and recommendations for clinical practice. We did not investigate the effect of coenzyme Q10 on several biomarkers, such as C‐reactive protein, high sensitivity troponin, myeloperoxidase, and uric acid, as we felt they were less relevant to the objectives of the review. Nevertheless, studying these outcomes in the future might enable a better understanding of the role of coenzyme Q10 in heart failure. </p> </section> <section id="CD008684-sec-0083"> <h3 class="title" id="CD008684-sec-0083">Quality of the evidence</h3> <p>As noted in the <a href="#CD008684-sec-0047">Risk of bias in included studies</a>, most of the included studies had unclear or high risks of bias. There were also multiple pooled outcome measures with wide confidence intervals, often crossing the line of no effect, which we assessed as imprecision. These two factors decreased the quality and certainty of the evidence. </p> <p>This was evident for five primary outcomes: risk of myocardial infarction, risk of stroke, left ventricular ejection fraction, exercise capacity, and adverse events. We found high levels of heterogeneity for one outcome (serum levels of coenzyme Q10); pooled analysis showed unexplained heterogeneity. Evidence derived from this review ranged from very low to moderate quality. Indeed, this confers the need for larger studies that are clear of risk of evidence evaluating coenzyme Q10. </p> </section> <section id="CD008684-sec-0084"> <h3 class="title" id="CD008684-sec-0084">Potential biases in the review process</h3> <p>We conducted our review according to a protocol, and following the recommendations of Cochrane. Per the protocol, we used the random‐effects model in our analyses. One limitation was the unavailability of data from the first phase of cross‐over studies; these data were not published, nor were they provided by the trial authors after we contacted them, except for <a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>. Therefore, we excluded all cross‐over studies expect for <a href="./references#CD008684-bbs2-0002" title="JPRN-UMIN000012604. Effect of the REduced form of COenzyme Q10 Supplementation on endothelial function in chronic heart failure (RECOQS). apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000012604 (date of registration 17 December 2013). Kawashima C, Matsuzawa Y, Konishi M, AkiyamaE , SuzukiH , SatoR , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single-center, randomized double-blind placebo-controlled crossover pilot study. American Journal of Cardiovascular Drugs2020;20(4):363-72. KawashimaC , MatsuzawaY , AkiyamaE , SatoR , KonishiM , SuzukiH , et al. Ubiquinol improves endothelial function in patients with heart failure with reduced ejection fraction: a single center, randomized double-blind placebo-controlled cross-over study. Circulation2016;134(Suppl 1):Abstract 14946. ">Kawashima 2016</a>. For variables reported in different ways in different studies, we were unable to pool data. This review combined participants with both heart failure with reduced ejection fraction (HFrEF), and heart failure with preserved ejection fraction (HFpEF). Given the differences in the pathophysiology and treatment of these two types of heart failure, separate analyses for each type would be beneficial in subsequent updates of this review. Finally, there is a lag time between the last search and the publication of this review; it is possible that new trials have been published. </p> </section> <section id="CD008684-sec-0085"> <h3 class="title" id="CD008684-sec-0085">Agreements and disagreements with other studies or reviews</h3> <p>One meta‐analysis concluded that the use of coenzyme Q10 in participants with congestive heart failure improved stroke volume, ejection fraction, cardiac output, cardiac index, and end diastolic volume index (<a href="./references#CD008684-bbs2-0119" title="SojaAM , MortensenSA . Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Molecular Aspects of Medicine1997;18 Suppl:S159-68. [PMID: 9266518]">Soja 1997</a>). </p> <p>A systematic review with a meta‐analysis of studies ranging from 3 to 12 months long, reported non‐significant trends towards increased ejection fraction and reduced mortality; they had an insufficient number of participants for meaningful results (<a href="./references#CD008684-bbs2-0115" title="RosenfeldtF , HiltonD , PepeS , KrumH . Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. BioFactors (Oxford, England)2003;18(1-4):91-100. [PMID: 14695924]">Rosenfeldt 2003</a>). </p> <p>A systematic review with a meta‐analysis concluded that the use of coenzyme Q10 in participants with heart failure improved ejection fraction more in participants who were not receiving angiotensin‐converting enzyme inhibitors, and improved cardiac output. Treatment periods ranged from one to six months (<a href="./references#CD008684-bbs2-0116" title="SanderS , ColemanCI , PatelAA , KlugerJ , WhiteCM . The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. Journal of Cardiac Failure2006;12(6):464-72. [PMID: 16911914]">Sander 2006</a>). </p> <p>A systematic review with a meta‐analysis of studies ranging from 4 to 28 weeks long concluded that the use of coenzyme Q10 in participants with congestive heart failure improved ejection fraction, and showed a trend towards improved NYHA functional class that did not reach statistical significance (<a href="./references#CD008684-bbs2-0082" title="FotinoAD , Thompson-PaulAM , BazzanoLA . Effect of coenzyme Q(10) supplementation on heart failure: a meta-analysis. American Journal of Clinical Nutrition2013;97(2):268-75. [PMID: 23221577]">Fotino 2013</a>). </p> <p>Compared to these previous reviews, we are uncertain as to whether the use of coenzyme Q10 in heart failure improves LVEF or not, since the evidence is of very low quality. However, our review shows that coenzyme Q10 in heart failure probably reduces all‐cause and cardiovascular mortality. Results in our review are limited by small studies that were at significant risk of bias. Thus, we are unable to draw robust conclusions. </p> <p>The original Cochrane review concluded that the use of coenzyme Q10 in participants with heart failure did not have an effect on mortality (<a href="./references#CD008684-bbs2-0094" title="MadmaniME , Yusuf SolaimanA , Tamr AghaK , MadmaniY , ShahrourY , EssaliA , et al. Coenzyme Q10 for heart failure. Cochrane Database of Systematic Reviews2014, Issue 6. Art. No: CD008684. [DOI: 10.1002/14651858.CD008684.pub2]">Madmani 2014</a>). However, this was derived from the only study that reported on mortality, which we excluded in the current review, due to lack of randomisation (<a href="./references#CD008684-bbs2-0012" title="AdarshK , KaurH , MohanV . Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). BioFactors (Oxford, England)2008;32(1-4):145-9. ">Adarsh 2008</a>). The original review also concluded no effect on LVEF. This does not contradict the current review, since the studies in the original review only reported short‐term follow‐up. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008684-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/urn:x-wiley:14651858:media:CD008684:CD008684-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow chart" data-id="CD008684-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_t/tCD008684-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow chart</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/full#CD008684-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008684-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/urn:x-wiley:14651858:media:CD008684:CD008684-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD008684-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_t/tCD008684-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/full#CD008684-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008684-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/urn:x-wiley:14651858:media:CD008684:CD008684-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies" data-id="CD008684-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_t/tCD008684-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/full#CD008684-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008684-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/urn:x-wiley:14651858:media:CD008684:CD008684-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Coenzyme Q10 versus control, Outcome 1: All cause mortality" data-id="CD008684-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_t/tCD008684-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Coenzyme Q10 versus control, Outcome 1: All cause mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/references#CD008684-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008684-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/urn:x-wiley:14651858:media:CD008684:CD008684-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Coenzyme Q10 versus control, Outcome 2: Myocardial infarction" data-id="CD008684-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_t/tCD008684-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Coenzyme Q10 versus control, Outcome 2: Myocardial infarction</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/references#CD008684-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008684-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/urn:x-wiley:14651858:media:CD008684:CD008684-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Coenzyme Q10 versus control, Outcome 3: Stroke" data-id="CD008684-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_t/tCD008684-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Coenzyme Q10 versus control, Outcome 3: Stroke</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/references#CD008684-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008684-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/urn:x-wiley:14651858:media:CD008684:CD008684-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Coenzyme Q10 versus control, Outcome 4: Revascularisation procedures" data-id="CD008684-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_t/tCD008684-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Coenzyme Q10 versus control, Outcome 4: Revascularisation procedures</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/references#CD008684-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008684-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/urn:x-wiley:14651858:media:CD008684:CD008684-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Coenzyme Q10 versus control, Outcome 5: Hospitalisation for heart failure" data-id="CD008684-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_t/tCD008684-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Coenzyme Q10 versus control, Outcome 5: Hospitalisation for heart failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/references#CD008684-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008684-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/urn:x-wiley:14651858:media:CD008684:CD008684-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Coenzyme Q10 versus control, Outcome 6: Left ventricular ejection fraction (%)" data-id="CD008684-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_t/tCD008684-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Coenzyme Q10 versus control, Outcome 6: Left ventricular ejection fraction (%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/references#CD008684-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008684-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/urn:x-wiley:14651858:media:CD008684:CD008684-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Coenzyme Q10 versus control, Outcome 7: Exercise capacity: treadmill exercise test duration (seconds)" data-id="CD008684-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_t/tCD008684-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Coenzyme Q10 versus control, Outcome 7: Exercise capacity: treadmill exercise test duration (seconds) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/references#CD008684-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008684-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/urn:x-wiley:14651858:media:CD008684:CD008684-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Coenzyme Q10 versus control, Outcome 8: Exercise capacity: metabolic equivalent on treadmill exercise test (METs)" data-id="CD008684-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_t/tCD008684-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Coenzyme Q10 versus control, Outcome 8: Exercise capacity: metabolic equivalent on treadmill exercise test (METs) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/references#CD008684-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008684-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/urn:x-wiley:14651858:media:CD008684:CD008684-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Coenzyme Q10 versus control, Outcome 9: Brain natriuretic peptide (pg/mL)" data-id="CD008684-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_t/tCD008684-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Coenzyme Q10 versus control, Outcome 9: Brain natriuretic peptide (pg/mL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/references#CD008684-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008684-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/urn:x-wiley:14651858:media:CD008684:CD008684-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Coenzyme Q10 versus control, Outcome 10: Serum levels of coenzyme Q10 (μg/mL)" data-id="CD008684-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_t/tCD008684-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Coenzyme Q10 versus control, Outcome 10: Serum levels of coenzyme Q10 (μg/mL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/references#CD008684-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008684-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/urn:x-wiley:14651858:media:CD008684:CD008684-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Coenzyme Q10 versus control, Outcome 11: Aderse events" data-id="CD008684-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_t/tCD008684-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Coenzyme Q10 versus control, Outcome 11: Aderse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/references#CD008684-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/media/CDSR/CD008684/image_n/nCD008684-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008684-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Coenzyme Q10 compared to placebo or conventional therapy for heart failure</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Coenzyme Q10 compared to placebo or conventional therapy for heart failure</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with heart failure<br/><b>Setting:</b> outpatient departments<br/><b>Intervention:</b> coenzyme Q10<br/><b>Comparison:</b> placebo or conventional therapy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or conventional therapy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with coenzyme Q10</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/><i>follow‐up: 26 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.58<br/>(0.35 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>420<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Coenzyme Q10 probably reduces all‐cause mortality</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>179 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000<br/>(63 to 170) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Myocardial infarction</b><br/><i>follow‐up: 26 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.62<br/>(0.27 to 9.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>420<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The results for the effect of coenzyme Q10 on risk of myocardial infarction are inconclusive.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000<br/>(2 to 88) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/><i>follow‐up: 26 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.18<br/>(0.02 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>420<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup><sup>,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The results for the effect of coenzyme Q10 on risk of stroke are inconclusive.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/>(1 to 41) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Hospitalisation for heart failure</b><br/><i>follow‐up: mean 19 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.62<br/>(0.49 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1061<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Coenzyme Q10 probably reduces hospitalisation for heart failure.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>276 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>171 per 1000<br/>(135 to 215) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Left ventricular ejection fraction (%)</b><br/><i>follow‐up: mean 8 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.77 higher<br/>(0.09 higher to 3.44 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>650<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d</sup><sup>,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of coenzyme Q10 on left ventricular ejection fraction (%). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exercise capacity</b> <br/><b>(assessed with treadmill exercise test (duration in seconds))</b><br/><i>follow‐up: mean 4 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 48.23 higher<br/>(24.75 lower to 121.2 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>f</sup><sup>,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of coenzyme Q10 on exercise capacity.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b><br/><i>follow‐up: mean 16 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.70<br/>(0.45 to 1.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>568<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup><sup>,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The results for adverse events associated with coenzyme Q10 are inconclusive.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000<br/>(71 to 174) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval;<b> MD</b> : mean difference; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty.</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty.</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty.</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty.</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to indirectness. The findings are applicable only to the characteristics of participants and dosing regimen as included in this one study. <br/><sup>b</sup>Downgraded by one level due to imprecision. The effect size has a very wide confidence interval that includes the possibilities of substantial harm, no difference, and a lower risk with coenzyme Q10. <br/><sup>c</sup>Downgraded by one level due to risk of bias. The included study that contributed most weight to the analysis had unclear risk for selection, detection, and reporting biases, and high risk for attrition bias. <br/><sup>d</sup>Downgraded by one level due to imprecision. The effect size has a very wide confidence interval that includes the possibility of only a minimal benefit with coenzyme Q10. <br/><sup>e</sup>Downgraded by two levels due to substantial risk of bias. Within the 7 included studies, selection bias was unclear in 6, performance bias was high in 1, detection bias was unclear in 3 and high in 1, attrition bias was high in 4, reporting bias was unclear in 3 and high in 1, and other bias was high in 1. <br/><sup>f</sup>Downgraded by two levels for imprecision. The effect size has a very wide confidence interval that includes the possibility of substantial harm, no difference, and a lower risk with coenzyme Q10. Also, the sample size is small. <br/><sup>g</sup>Downgraded by one level due to risk of bias. The 3 included studies had unclear risk of selection and detection biases, and high risk of attrition bias. Two of them also had unclear risk of reporting bias. <br/><sup>h</sup>Downgraded by one level due to indirectness. The findings are applicable only to the characteristics of participants and dosing regimen as included in the study that contributed the most weight to this analysis. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Coenzyme Q10 compared to placebo or conventional therapy for heart failure</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/full#CD008684-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008684-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Coenzyme Q10 versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Revascularisation procedures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Hospitalisation for heart failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.49, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Left ventricular ejection fraction (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.09, 3.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Exercise capacity: treadmill exercise test duration (seconds) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>48.23 [‐24.75, 121.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Exercise capacity: metabolic equivalent on treadmill exercise test (METs) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Brain natriuretic peptide (pg/mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐91.97 [‐103.11, ‐80.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Serum levels of coenzyme Q10 (μg/mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.09, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Studies with coenzyme Q10 dose &gt;200 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.96, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 Studies with maximum coenzyme Q10 dose of 200 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.19, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Aderse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.45, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Coenzyme Q10 versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008684.pub3/references#CD008684-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008684.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD008684-note-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD008684-note-0010">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008684-note-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008684-note-0009">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008684-note-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD008684-note-0014">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD008684-note-0006">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD008684-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD008684-note-0016">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD008684-note-0005">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD008684-note-0013">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008684-note-0011">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008684-note-0012">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008684\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008684\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008684\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008684\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008684\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008684\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008684\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008684\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008684\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008684\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008684\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008684\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008684\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008684\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008684\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008684\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008684\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008684\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008684.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008684.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008684.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008684.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008684.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724868323"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008684.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724868327"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008684.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e6d513888f4ca',t:'MTc0MDcyNDg2OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 